[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 518
1. Kim HR, Kim TH, Chung JH, Yoon HI, Lee CT, Kang CH, Jheon S, Sung SW, Kim JH, Jeon C: The detection of peripheral lung cancer by MAGE A1-6 RT-nested PCR in bronchial washing specimens. Lung Cancer; 2009 Aug;65(2):166-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The detection of peripheral lung cancer by MAGE A1-6 RT-nested PCR in bronchial washing specimens.
  • BACKGROUND: With expansion of lung cancer screening by computed tomography (CT) and increased incidence of adenocarcinoma, we encountered more peripheral nodules to be identified.
  • MATERIALS AND METHODS: Forty-two patients with bronchoscopically invisible peripheral lung nodules were studied.
  • Bronchoscopic washing specimens were collected by instilling 20ml of normal saline into a tumor bearing segment and retrieving samples.
  • Twenty-eight lesions were diagnosed as lung cancers and 14 as benign lung diseases.
  • We evaluated MAGE A1-6 RT-nested PCR, cytology, and PCNB results and analyzed them according to histologic cell types and tumor sizes.
  • The sensitivity of conventional cytology was significantly lower than that of MAGE RT-nested PCR or PCNB regardless of tumor histology p=.04, p=.025, respectively, in adenocarcinoma; p=.035, p=.04, respectively, in squamous cell carcinoma).
  • In terms of tumor size, the corresponding detection rates were 73.3%, 6.7% and 73.3% for tumors smaller than 3cm (N=15), and 61.5%, 38.5% and 72.7% for tumors larger than 3cm (N=13).
  • CONCLUSIONS: MAGE A1-6 RT-nested PCR showed higher detection rates in the bronchial washes of peripheral lung cancer patients than conventional cytology testing.
  • This method is simple and robust, and it could be effectively utilized as a peripheral lung cancer detection tool in clinical laboratories.
  • [MeSH-major] Antigens, Neoplasm / analysis. Bronchoalveolar Lavage Fluid / chemistry. Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Proteins / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168258.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / MAGEA4 protein, human; 0 / MAGEA6 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


2. Xi L, Coello MC, Litle VR, Raja S, Gooding WE, Yousem SA, El-Hefnawy T, Landreneau RJ, Luketich JD, Godfrey TE: A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res; 2006 Apr 15;12(8):2484-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients.
  • Occult lymph node metastasis (micrometastasis) is a good prognostic indicator in non-small cell lung cancer (NSCLC) and could be used to direct adjuvant chemotherapy in stage I patients.
  • This study was designed to evaluate molecular markers for detection of occult lymph node metastasis in NSCLC, define the best marker or marker combination to distinguish positive from benign lymph nodes, and evaluate these markers in lymph nodes from pathologically node-negative (pN(0)) NSCLC patients.
  • Potential markers were identified through literature and database searches and all markers were analyzed by quantitative reverse transcription-PCR in a primary screen of six NSCLC specimens and 10 benign nodes.
  • Selected markers were further evaluated on 21 primary NSCLC specimens, 21 positive nodes, and 21 benign nodes, and the best individual markers and combinations were identified.
  • A combination of three markers was further validated on an independent set of 32 benign lymph nodes, 38 histologically positive lymph nodes, and 462 lymph nodes from 68 pN(0) NSCLC patients.
  • A combination of three markers (SFTPB, TACSTD1, and PVA) was identified that provided perfect classification of benign and positive nodes in all sample sets.
  • PVA and SFTPB are particularly powerful in tumors of squamous and adenocarcinoma histologies, respectively, whereas TACSTD1 is a good general marker for NSCLC metastasis.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):389-98 [16495705.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):39-46 [11249047.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Int J Cancer. 2001 Jul 15;93(2):162-71 [11410861.001]
  • [Cites] J Pathol. 2001 Jul;194(3):298-302 [11439361.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491 [11882819.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2930-6 [12089221.001]
  • [Cites] Clin Chem. 2003 Feb;49(2):312-5 [12560358.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):611-8 [12845661.001]
  • [Cites] Am J Surg. 2003 Oct;186(4):324-9 [14553843.001]
  • [Cites] Clin Lung Cancer. 2004 Jan;5(4):214-25 [14967073.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2671-80 [15226334.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3417-20 [7542169.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4283-6 [7671236.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Oct;114(4):535-43 [9338638.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1410-5 [9801000.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):19-24 [10458213.001]
  • [Cites] Lancet. 1999 Sep 11;354(9182):896-900 [10489948.001]
  • [Cites] Chest. 2005 Feb;127(2):430-7 [15705978.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1099-109 [15709177.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2147-56 [15781625.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s [16000606.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5022s-5026s [16000607.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):429-35 [10646900.001]
  • (PMID = 16638856.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094059-04; United States / NCI NIH HHS / CA / R01 CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059; United States / NCI NIH HHS / CA / CA094059-03; United States / NCI NIH HHS / CA / R01 CA094059-01; United States / NCI NIH HHS / CA / R01 CA090665; United States / NCI NIH HHS / CA / R01 CA094059-03; United States / NCI NIH HHS / CA / R01CA90665; United States / NCI NIH HHS / CA / CA094059-02; United States / NCI NIH HHS / CA / CA094059-05; United States / NCI NIH HHS / CA / R01 CA094059-02; United States / NCI NIH HHS / CA / R01 CA094059-04; United States / NCI NIH HHS / CA / CA094059-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / DSG3 protein, human; 0 / Desmoglein 3; 0 / EPCAM protein, human; 0 / Pulmonary Surfactant-Associated Protein B
  • [Other-IDs] NLM/ NIHMS24707; NLM/ PMC1933488
  •  go-up   go-down


3. Keylock JB, Galvin JR, Franks TJ: Sclerosing hemangioma of the lung. Arch Pathol Lab Med; 2009 May;133(5):820-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing hemangioma of the lung.
  • We present a brief review of sclerosing hemangioma, an uncommon but histologically distinctive neoplasm of the lung.
  • Sclerosing hemangiomas typically present as asymptomatic, peripheral, solitary, well-circumscribed lesions in women with a mean age at diagnosis in the fifth decade.
  • Sclerosing hemangioma of the lung is generally considered to be a benign lesion, and surgical excision is curative without the need for additional treatment.
  • [MeSH-major] Lung / pathology. Pulmonary Sclerosing Hemangioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma / diagnosis. Carcinoma / secondary. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Male. Prognosis. Radiography, Thoracic. Respiratory Mucosa / metabolism. Respiratory Mucosa / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415961.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


Advertisement
4. Shimoyama T, Kimura B: [Peripheral intrapulmonary lipoma: report of a case]. Kyobu Geka; 2009 Dec;62(13):1186-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest computed tomography showed a well-defined nodule of 1 cm diameter periphery in lower lobe of the right lung.
  • The differential diagnosis included benign lung tumors, such as intrapulmonary lymph nodes, granuloma etc.
  • To make diagnosis, a wedge resection of the pulmonary nodule was performed.
  • The tumor was diagnosed as a lipoma.
  • Although peripheral intrapulmonary lipoma is very rare, it should be kept in mind in the differential diagnosis of an intrapulmonary nodule.
  • [MeSH-major] Lipoma / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999101.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 5
  •  go-up   go-down


5. Civi K, Ciftçi E, Gürlek Olgun E, Erginel S, Ozkan R, Metintaş M: Peripheral intrapulmonary lipoma: a case report and review of the literature. Tuberk Toraks; 2006;54(4):374-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipomas are common benign tumours, but intrathoracic lipomas are rare and peripheral lung lipomas are exceptionally rare.
  • We report a case of lipoma arising in the periphery of the left lower lung in a 54-year old woman.
  • A wedge resection was done of the left lung and the microscopic findings revealed lipoma of the lung.
  • The present paper recapitulates the macroscopic and microscopic features, the treatment and the differential diagnosis of this rare neoplasm.
  • [MeSH-major] Lipoma / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Chest Pain / etiology. Cough / etiology. Diagnosis, Differential. Female. Humans. Middle Aged. Respiratory Sounds / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203425.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 12
  •  go-up   go-down


6. Walsh SN, Sangüeza OP: PEComas: a review with emphasis on cutaneous lesions. Semin Diagn Pathol; 2009 Aug;26(3):123-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The connection between angiomyolipoma (AML) of the kidney, clear cell sugar tumor (CCST) of the lung, and pulmonary lymphangioleiomyoma (LAM), was progressively discovered because of the histologic and immunophenotypic similarities between the three tumors and their frequent association with tuberous sclerosis complex (TSC).
  • PEC tumors (or PEComas), other than AML, CCST, and LAM, are not associated with TSC and typically occur in middle-aged adult females.
  • Most reported cutaneous PEComas follow a benign course, however, a malignant case has been reported.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Female. Humans. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2016 Feb;38(2):165-6 [26825164.001]
  • (PMID = 20043511.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  • [Number-of-references] 65
  •  go-up   go-down


7. Aïssaoui R, Turki Z, Achiche A, Balti MH, Ben Slama C, Zbiba M: [Adrenal metastasis of a papillary thyroid cancer]. Ann Endocrinol (Paris); 2006 Sep;67(4):364-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Métastase surrénalienne d'un cancer papillaire de la thyroïde.
  • A 63-year-old woman had undergone 15 years earlier left lobo-ishmectomy for a papillary thyroid cancer (PTC) and 7 years earlier right adrenalectomy for a tumor.
  • Histologic examination showed a benign cortical tumor.
  • According to the hormone evaluation it was a non-functional tumor.
  • Re-reading the histology slide of the first adrenalectomy agreed with the diagnosis.
  • Distant spread may occur to bone or lung, but exceptionally to the adrenal gland.
  • The adrenal localization is often associated with lung or bone metastasis.
  • [MeSH-minor] Adrenalectomy. Female. Humans. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed. Treatment Outcome


8. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K: PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol; 2006 Aug;11(4):286-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
  • FDG-PET provides information that is not obtainable with other imaging modalities, and is very effective in the diagnosis and management of patients with various types of cancers.
  • PET and/or PET/CT using FDG is clinically useful in the detection of cancer, the differentiation of malignant and benign lesions, the staging of cancer before therapy, and the assessment of cancer therapy, as well as for determining the recurrence after therapy of most cancers, including lung cancer, gastrointestinal cancer, breast cancer, and malignant lymphoma.
  • PET/CT has become the new standard approach to imaging in the diagnosis and management of many cancer patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / diagnosis. Neoplasms / diagnostic imaging. Positron-Emission Tomography / methods. Tomography, Emission-Computed / methods
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / diagnostic imaging. Carcinoma / diagnosis. Carcinoma / diagnostic imaging. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / diagnostic imaging. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / diagnostic imaging. Lymphoma / diagnosis. Lymphoma / diagnostic imaging. Neoplasm Staging / methods. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Oct 20;23 (30):7445-53 [16157939.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv23-9 [12746265.001]
  • [Cites] Ann Surg Oncol. 2005 Jul;12(7):561-9 [15889211.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2927-33 [10898336.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2785-808 [15837727.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4577-80 [15837974.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4652-61 [15837965.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1811-7 [7562048.001]
  • [Cites] Chest. 2004 Jun;125(6):2294-9 [15189954.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1676-88 [10764428.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):319-23 [9527052.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23 (2):315-40; quiz 533 [12640150.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):267-73 [15695786.001]
  • [Cites] Semin Nucl Med. 2002 Jan;32(1):6-12 [11839070.001]
  • [Cites] Radiology. 1998 Mar;206(3):755-60 [9494497.001]
  • [Cites] Blood. 2003 May 15;101(10 ):3875-6 [12531812.001]
  • [Cites] Radiology. 2006 Apr;239(1):34-49 [16567482.001]
  • [Cites] Radiology. 2004 May;231(2):305-32 [15044750.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3495-502 [11032590.001]
  • [Cites] J Nucl Med. 2004 Dec;45(12 ):1989-98 [15585472.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):14-22 [16391182.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):104-12 [8271030.001]
  • [Cites] J Nucl Med. 2002 Apr;43(4):492-9 [11937593.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Gut. 2006 Jan;55(1):10-2 [16344572.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1784-8 [14602860.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1016-20 [9627336.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1144-50 [16000283.001]
  • [Cites] Gut. 2006 Jan;55(1):68-73 [15970580.001]
  • [Cites] Chest. 2004 Nov;126(5):1656-66 [15539740.001]
  • [Cites] Blood. 1998 Jun 15;91(12 ):4464-71 [9616140.001]
  • [Cites] Cancer. 2000 Dec 15;89(12 ):2547-54 [11135214.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):426-31 [16513611.001]
  • [Cites] J Nucl Med. 2000 Jul;41(7):1177-89 [10914907.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):862-9 [11313174.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4643-51 [15837966.001]
  • [Cites] Radiology. 2006 Feb;238(2):405-22 [16436809.001]
  • [Cites] J Nucl Med. 2004 Dec;45(12 ):2058-62 [15585482.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] Chest. 2004 Jun;125(6):2300-8 [15189955.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1689-95 [10764429.001]
  • [Cites] J Nucl Med. 2001 Jul;42(7):989-92 [11438616.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Apr;127(4):1087-92 [15052206.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):451-69 [16513615.001]
  • [Cites] Br J Surg. 2004 Aug;91(8):1004-9 [15286962.001]
  • [Cites] J Nucl Med. 2000 Aug;41(8):1369-79 [10945530.001]
  • (PMID = 16937302.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 51
  •  go-up   go-down


9. Ioncica AM, Malos A, Crisan E, Popescu C, Saftoiu A, Ciurea T: State-of-the art endoscopic imaging in lung cancer: should specialties collide or concur? J Gastrointestin Liver Dis; 2010 Mar;19(1):93-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State-of-the art endoscopic imaging in lung cancer: should specialties collide or concur?
  • Endoscopic ultrasound has been recently established as a routine diagnostic and staging procedure in lung cancer patients, mainly because of the possibility of tissue sampling.
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) permits the assessment of the tumors in the anterior mediastinum.
  • Based on previously published literature, it is obvious that this minimally invasive procedure now offers the possibility of tissue diagnosis in mediastinal masses including primary tumours or secondary lesions from both benign and malignant diseases.
  • [MeSH-major] Biopsy, Fine-Needle. Bronchoscopy. Echocardiography, Transesophageal. Endosonography. Lung Neoplasms / diagnosis. Ultrasonography, Interventional
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361084.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  •  go-up   go-down


10. Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C, Wahl A, Glatting G, Mottaghy FM, Mattfeldt T, Neumaier B, Reske SN: Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging; 2005 May;32(5):525-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of imaging proliferative activity in lung nodules.
  • In this prospective study, we examined the accuracy of FLT for differentiation of benign from malignant lung lesions and for tumour staging.
  • RESULTS: Histopathology revealed malignant lung tumours in 32 patients (20 non-small cell lung cancer, 1 small cell lung cancer, 1 pulmonary carcinoid, 1 non-Hodgkin's lymphoma, nine metastases from extrapulmonary tumours) and benign lesions in 15 patients.
  • FLT-PET was false negative in two patients with non-small cell lung cancer, in the patient with a pulmonary carcinoid and in three patients with lung metastases.
  • The sensitivity of FLT-PET for detection of lung cancer was 90%, the specificity 100% and the accuracy 94%.
  • Fifteen out of 21 patients with lung cancer had mediastinal lymph node metastases.
  • CONCLUSION: FLT-PET has a high specificity for the detection of malignant lung tumours.
  • Compared with FDG, FLT-PET is less accurate for N-staging in patients with lung cancer and for detection of lung metastases.
  • FLT-PET therefore cannot be recommended for staging of lung cancer.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / classification. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radionuclide Imaging. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9 [12397465.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12 ):1927-32 [14660718.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3331-4 [12067968.001]
  • [Cites] J Nucl Med. 2001 May;42(5):721-5 [11337566.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10 ):1754-8 [15471845.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Apr;36(4):808-18 [1503443.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1174-81 [12192562.001]
  • [Cites] Eur J Nucl Med. 1994 Sep;21(9):930-6 [7995286.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):111-8 [11134203.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):695-700 [15073267.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1426-31 [12960187.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10 (5):1685-90 [15014020.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):165-9 [11926377.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1596-604 [11696627.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):104-12 [8271030.001]
  • [Cites] Nucl Med Biol. 1996 Jan;23 (1):17-22 [9004909.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jul;30(7):988-94 [12739071.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):928 [15034675.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3791-8 [12839975.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Oct;30(10 ):1407-12 [12898201.001]
  • [Cites] Radiographics. 1999 Jan-Feb;19(1):61-77; quiz 150-1 [9925392.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1210-7 [12215561.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):519-25 [15001697.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):615-21 [9973209.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1688-98 [12468521.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):169-78 [15129698.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3201-6 [10506619.001]
  • [Cites] J Nucl Med. 1984 Jul;25(7):759-64 [6610731.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2500-4 [11289121.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3315-23 [12429617.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1432-4 [12960188.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):720-4 [14991243.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • (PMID = 15599526.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; PG53R0DWDQ / alovudine
  •  go-up   go-down


11. Khan A: ACR Appropriateness Criteria on solitary pulmonary nodule. J Am Coll Radiol; 2007 Mar;4(3):152-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The solitary pulmonary nodule is traditionally defined as a relatively spherical opacity 3 cm or less in diameter surrounded by lung parenchyma.
  • However, only 2 findings are considered to be sufficient to preclude further evaluation: calcification in a benign pattern and stability in size for more than 2 years.
  • [MeSH-major] Lung / pathology. Lung Neoplasms / diagnosis. Positron-Emission Tomography / standards. Solitary Pulmonary Nodule / diagnosis. Tomography, X-Ray Computed / standards
  • [MeSH-minor] Biopsy, Fine-Needle. Bronchoscopy / methods. Contrast Media. Diagnosis, Differential. Diagnostic Imaging / standards. Female. Humans. Immunohistochemistry. Male. Monitoring, Physiologic. Neoplasm Staging. Risk Assessment. Sensitivity and Specificity. Societies, Medical / standards. Thoracoscopy / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17412254.001).
  • [ISSN] 1558-349X
  • [Journal-full-title] Journal of the American College of Radiology : JACR
  • [ISO-abbreviation] J Am Coll Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 30
  •  go-up   go-down


12. Liu YQ, Zhang HL, Gao WJ, Lan X, Yuan BJ, Zou JM: [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan;26(1):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
  • OBJECTIVE: To investigate the clinical value of pleural effusion lung ProGRP, neuron specific enolase (NSE), cytokeratin fragment 19 (CYFRA21-1), carcino-embryonic antigen (CEA), carbohydrate antigen 153 (CA153), carbohydrate antigen 19 - 9 (CA19-9) in differential diagnosis and histological typing of malignant pleural effusion caused by lung cancer.
  • METHODS: All the 171 patients with malignant hydrothorax caused by lung cancer were from coal-mine area of Kailuan.
  • They were divided into the small cell lung cancer (SCLC) group (n = 39), the adenocarcinoma group (n = 99) and the squamous cell carcinoma group (n = 37).
  • The patients with benign pleural effusion served as the controls (n = 30).
  • RESULTS: Youden index and the accurate rate of pleural effusion ProGRP + NSE (sequence test) were the highest in the diagnosis of malignant hydrothorax caused by SCLC.
  • CEA + CA153 + CA19-9 (sequence test) was the highest in the diagnosis of malignant hydrothorax caused by adenocarcinoma.
  • CYFRA21-1 + CEA + CA153 (on parallel test) were the highest in the diagnosis of malignant hydrothorax caused by squamous cell carcinoma.
  • CONCLUSION: The first pleural effusion tumor markers of malignant hydrothorax caused by the SCLC, adenocarcinoma of lung, and lung squamous cell carcinoma are ProGRP, CEA and CYFRA21-1, respectively.
  • The best combinations of pleural effusion tumor marker in diagnosis of malignant hydrothorax caused by the SCLC, adenocarcinoma of lung, lung squamous cell carcinoma and lung cancer are the combined detection of ProGRP + NSE (sequence test), combined detection of CEA + CA153 + CA19-9 (sequence test), the combined detection of CYFRA21-1 + CEA + CA153 (on parallel test) and ProGRP + CYFRA21-1 + CEA (on parallel test), respectively.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Diagnosis, Differential. Female. Humans. Keratin-19 / analysis. Male. Middle Aged. Peptide Fragments / analysis. Recombinant Proteins / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302890.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / CA153 protein, human; 0 / Keratin-19; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / antigen CYFRA21.1; 0 / pro-gastrin-releasing peptide (31-98)
  •  go-up   go-down


13. Schmidt B, Engel E, Carstensen T, Weickmann S, John M, Witt C, Fleischhacker M: Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection? Lung Cancer; 2005 Apr;48(1):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection?
  • In cancer patients levels of free DNA seem to be higher than in non-tumor controls and the detectable nucleic acids are partly of tumor origin.
  • We asked whether free RNA can be detected as well in cell-free bronchial lavage fluid (BLF) supernatant, and whether quantification of free RNA allows to discriminate between tumor and non-tumor patients.
  • 73 patients with lung cancer (NSCLC n=62, SCLC n=11) and 56 patients with non-malignant lung diseases were included.
  • RNA concentration in the BLF from tumor patients was higher than in patients with a benign lung disease (p=0.009).
  • In conclusion, quantification of intact RNA isolated from BLF supernatant and from serum might become a valuable tool for differentiation between tumor and non-tumor patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. RNA / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bronchoalveolar Lavage Fluid / chemistry. DNA, Neoplasm. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15777983.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 63231-63-0 / RNA
  •  go-up   go-down


14. Thunnissen FB, Kerr KM, Brambilla E, Comin CE, Franklin WA, Guldhammerskov B, Westra WH, Flieder DB: EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer. Eur Respir J; 2006 Dec;28(6):1186-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EU-USA pathology panel for uniform diagnosis in randomised controlled trials for HRCT screening in lung cancer.
  • Randomised controlled trials for lung cancer screening using high-resolution computed tomography are now underway.
  • In order to allow effective future comparison of the different trials, as well as strengthening conclusions based upon the analysis of larger data sets, uniformity and consistency of pathology diagnosis are essential.
  • The kappa 2 score distinguished between categories denoting benign and malignant lesions.
  • In conclusion, this study demonstrates that screen-detected cases pose particular problems for pathologists and that a trained pathology panel serving randomised controlled trials is likely to lead to more consistent and accurate tissue diagnosis.
  • [MeSH-major] Lung / pathology. Lung Neoplasms / diagnosis. Mass Screening. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Histological Techniques / methods. Histological Techniques / standards. Humans. Neoplasm Staging. Observer Variation. Pathology, Clinical. Reproducibility of Results


15. Peng HQ, Greenwald BD, Tavora FR, Kling E, Darwin P, Rodgers WH, Berry A: Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas. Diagn Cytopathol; 2008 May;36(5):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas.
  • We reviewed the cytologic and histologic diagnoses and EUS report of 77 consecutive patients who had undergone EUS-FNA preoperative staging for esophageal, lung, and pancreatic cancers at our institution.
  • We compared cytologically malignant and benign lymph node groups with eight EUS parameters including the total number of lymph nodes found by EUS, the shape, margin, long axis, short axis, echogenicity, location of the lymph node, and EUS tumor staging.
  • Lymph nodes found in an abdominal location in esophageal and lung cancer are likely malignant.
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymphatic Metastasis / pathology. Neoplasm Staging. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418852.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Wallowy P, Diener J, Grünwald F, Kovács AF: 18F-FDG PET for detecting metastases and synchronous primary malignancies in patients with oral and oropharyngeal cancer. Nuklearmedizin; 2009;48(5):192-9; quiz N42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In 74 of 80 evaluable cases, PET showed the primary tumour (92.5%).
  • Main sites were the lung, the upper aerodigestive tract, and the gastrointestinal system.
  • In the other 58 cases (69%), where the suspect lesions were confirmed as benign, mean SUV was 2.65 (range 0.7-6.5) (difference statistically significant).
  • [MeSH-major] Fluorodeoxyglucose F18. Mouth Neoplasms / pathology. Mouth Neoplasms / radionuclide imaging. Neoplasm Metastasis / radionuclide imaging. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radionuclide imaging
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Middle Aged. Neoplasm Staging. Palatal Neoplasms / pathology. Palatal Neoplasms / radionuclide imaging. Positron-Emission Tomography. Retrospective Studies. Tongue Neoplasms / pathology. Tongue Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623408.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Kim K, Kim HK, Park JS, Chang SW, Choi YS, Kim J, Shim YM: Video-assisted thoracic surgery lobectomy: single institutional experience with 704 cases. Ann Thorac Surg; 2010 Jun;89(6):S2118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: During the past decade, video-assisted thoracic surgery (VATS) lobectomy has been performed with increasing frequency in patients with early-stage non-small cell lung cancer (NSCLC).
  • RESULTS: Between 2003 and 2008, 704 patients underwent VATS lobectomy for the following indications: NSCLC (n = 548), carcinoid tumors (n = 7), pulmonary metastases (n = 22), and benign diseases (n = 127).
  • CONCLUSIONS: Video-assisted thoracoscopic surgery lobectomy is a technically feasible and safe operation with excellent survival for early-stage lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Survival Rate. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20493994.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Koh MS, Tee A, Wong P, Antippa P, Irving LB: Advances in lung cancer diagnosis and staging: endobronchial ultrasound. Intern Med J; 2008 Feb;38(2):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in lung cancer diagnosis and staging: endobronchial ultrasound.
  • BACKGROUND: Endobronchial ultrasound (EBUS) is an accurate and relatively less invasive procedure for the diagnosis of lung lesions and mediastinal lymph node staging for lung cancer.
  • METHODS: Consecutive patients who underwent EBUS-transbronchial lung biopsy (EBUS-TBLB) for biopsy of peripheral pulmonary lesions or for transbronchial needle aspiration (TBNA) of mediastinal lymph node enlargement were included in this audit.
  • The average size of the lung lesions biopsied was 3.5 cm and 62% were located in the upper lobes.
  • Malignancy was diagnosed in 14 cases and a benign aetiology in four.
  • Malignancy was diagnosed in 10 cases on TBNA and 4 cases had benign pathology.
  • CONCLUSION: EBUS is safe and an effective method for both, diagnosis of peripheral pulmonary lesions and staging for lung cancer.
  • [MeSH-major] Bronchi / pathology. Endosonography. Lung Neoplasms / pathology. Lung Neoplasms / ultrasonography. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. Humans. Male. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med J. 2008 Feb;38(2):75-6 [18290825.001]
  • (PMID = 17916175.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


20. Ozbudak IH, Dertsiz L, Bassorgun CI, Ozbilim G: Giant cystic chondroid hamartoma of the lung. J Pediatr Surg; 2008 Oct;43(10):1909-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cystic chondroid hamartoma of the lung.
  • Pulmonary hamartoma composed of an abnormal mixture of mesenchymal elements is the most common benign neoplasm in the lung.
  • Chest computed tomography revealed a heterogeneous mass filling the middle and the lower lobes of the right lung.
  • We believe this is the first case of 'giant cystic chondroid hamartoma of the lung' described in childhood.
  • We suggest that giant cystic pulmonary hamartoma should be included in the differential diagnosis of large intrathoracic masses in children.
  • [MeSH-major] Cysts / surgery. Hamartoma / surgery. Lung Diseases / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adipose Tissue / pathology. Calcinosis / pathology. Calcinosis / radiography. Calcinosis / surgery. Cartilage / pathology. Child. Diagnosis, Differential. Epithelium / pathology. Humans. Incidental Findings. Lung Neoplasms / diagnosis. Male. Thoracotomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926231.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Tian Q, Chen LA, Wang HS, Zhu BH, Tian L, Yang Z, An Y: Endobronchial ultrasound-guided transbronchial needle aspiration of undiagnosed mediastinal lymphadenopathy. Chin Med J (Engl); 2010 Aug;123(16):2211-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: EBUS-TBNA was diagnostic in 33 (63%) patients, with diagnosis of lung cancer in 23 patients (14 patients of small cell lung cancer, eight patients with adenocarcinoma, and one patient of squamous carcinoma).
  • The sensitivity, specificity, and positive and negative predictive value of EBUS-TBNA for the diagnosis of neoplastic disease were 85%, 100%, 100%, and 50% respectively.
  • Among the 16 sarcoidosis patients, who were diagnosed by a combination of the clinical and radiological information as well as pathological results obtained by EBUS-TBNA, nine of them had granulomas and benign lymphoid cells detected by EBUS-TBNA.
  • The sensitivity, specificity, and positive and negative predictive value of EBUS-TBNA for the diagnosis of sarcoidosis were 56%, 100%, 100%, and 13%, respectively.
  • Five patients with no definite diagnosis from EBUS-TNBA examination are under close follow-up.
  • It also adds pathological information needed to make the diagnosis of sarcoidosis.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Endosonography / methods. Lung Neoplasms / diagnosis. Lymphatic Diseases / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bronchi / pathology. Bronchi / ultrasonography. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819667.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Ali TZ, Epstein JI: Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2007 May;31(5):697-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common methods of diagnosis was transurethral resection (TURP) (n=29) and needle biopsy (n=9).
  • Infiltration around benign glands was seen in 10 (36%) cases, with predominantly small nests and AC-P.
  • Metastases developed in 4/29 patients: 1 in lung, 1 in lung and liver, 1 in lung, bone and liver, 1 in penile urethra.
  • Basal cell carcinomas are rare tumors with a broad morphologic spectrum.
  • These tumors predominantly show an indolent course with local infiltrative behavior.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Combined Modality Therapy. Humans. Male. Middle Aged. Mitosis. Neoplasm Recurrence, Local. Retrospective Studies. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460452.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


23. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary.
  • Of the 60 FVPC, 23 tumors (38%) were positive for IMP3, with 13 of these (22%) showing very strong staining (3+).
  • Of the 32 FC, 22 tumors (69%) were positive, with seven (22%) showing very strong staining (3+).
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


24. Morikawa M, Demura Y, Mizuno S, Ameshima S, Ishizaki T, Okazawa H: FDG positron emission tomography imaging of drug-induced pneumonitis. Ann Nucl Med; 2008 May;22(4):335-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies have reported the findings of fluorine-18-labeled fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) in benign lung disease with diffuse pulmonary injury; however, the characteristics and effectiveness of FDG-PET imaging for interstitial pneumonitis have not been substantiated.
  • The present cases show very interesting FDG-PET imaging findings of diffuse lung disease.
  • [MeSH-minor] Aged. Anxiety Disorders / drug therapy. Anxiety Disorders / etiology. Brain Neoplasms / complications. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Dibenzothiazepines / adverse effects. Dibenzothiazepines / therapeutic use. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / adverse effects. Paclitaxel / therapeutic use. Positron-Emission Tomography. Quetiapine Fumarate. Sensitivity and Specificity. Tomography, X-Ray Computed. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535887.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dibenzothiazepines; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 2S3PL1B6UJ / Quetiapine Fumarate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. O JH, Yoo IeR, Kim SH, Sohn HS, Chung SK: Clinical significance of small pulmonary nodules with little or no 18F-FDG uptake on PET/CT images of patients with nonthoracic malignancies. J Nucl Med; 2007 Jan;48(1):15-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nodules with clearly benign or metastatic findings on CT were excluded.
  • The subjects were studied by 3 variables: (i) solitary versus multiple nodules, (ii) presence of accompanying benign lung lesion versus absence, and (iii) imperceptible (18)F-FDG uptake versus faint (18)F-FDG uptake.
  • On the other hand, there was a statistically significant difference (P = 0.040) between the accompanying lung lesion present (8.3%) and absent (24.7%) groups.
  • CONCLUSION: For patients with incidental lung nodules of indeterminate nature with no (18)F-FDG uptake or uptake less than that of the mediastinum on PET/CT images, >19% of the cases turned out to be malignant.
  • The nodule was more likely to be malignant when no other benign pulmonary lesions could be identified elsewhere in the lung field.
  • Thus, regardless of the number of nodules and (18)F-FDG uptake, tissue confirmation or close imaging follow-up is necessary when small nodules with imperceptible or faint (18)F-FDG activity are present on the PET/CT images, especially in the absence of accompanying benign lung lesions.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Lung / radionuclide imaging. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Neoplasms / diagnosis. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Models, Statistical. Neoplasm Metastasis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204694.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Choi US, Alleman AR, Choi JH, Kim HW, Youn HJ, Lee CW: Cytologic and immunohistochemical characterization of a lung carcinoid in a dog. Vet Clin Pathol; 2008 Jun;37(2):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic and immunohistochemical characterization of a lung carcinoid in a dog.
  • An 11-year-old neutered male Yorkshire Terrier was presented to the Haemaru Referral Animal Hospital with a history of unresponsive tracheal collapse and an incidental finding of a lung nodule in the left caudal lung lobe on radiography.
  • A caudal lung lobectomy was performed, and histologic evaluation of the mass revealed round to polygonal cells with abundant eosinophilic granular cytoplasm and round nuclei with mild anisokaryosis and 0-3 mitotic figures per high-power field.
  • Cells were arranged in packets separated by fine fibrovascular stroma, suggestive of a pulmonary neuroendocrine neoplasm, specifically a carcinoma/carcinoid.
  • With these findings the tumor was diagnosed as a primary lung carcinoid.
  • Eleven months after resection, there was no evidence of tumor regrowth or metastasis.
  • The absence of necrosis, few mitotic figures, minimal pleomorphism, and benign behavior of this tumor resembled those of a typical carcinoid in humans.


27. El Demellawy D, Saleh R, Daya D, Alowami S: Malignant giant cell tumor of the vulva. Int J Gynecol Pathol; 2010 Jan;29(1):93-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant giant cell tumor of the vulva.
  • Giant cell malignant fibrous histiocytoma or giant cell tumor of the soft parts (GCTSP) is a rare soft tissue tumor.
  • GCTSP has an unpredictable behavior; the majority of the reported cases showed benign histology and those that showed malignant morphologic features were extremely rare.
  • Histologic features and the immunoprofile of the tumor and differential diagnosis are discussed in detail.
  • [MeSH-major] Giant Cell Tumors / secondary. Neoplasm Recurrence, Local / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Fatal Outcome. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952930.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Khadilkar UN, Kumar S, Prabhu PP, Kamath M: Mucoepidermoid carcinoma of lung: a case report. Indian J Pathol Microbiol; 2007 Jul;50(3):560-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of lung: a case report.
  • Mucoepidermoid lung tumours are uncommon neoplasms comprising of 0.2% of all the lung tumours and historically included under the term bronchial adenomas.
  • This is a case report of a bronchial tumour in the hilar region present since 3 years.
  • The neoplasm could be easily classified as a mucoepidermoid tumour of low malignant potential, as it resembled the histologically identical lesion in the main salivary glands.
  • The case is reported for its rarity and for the histological evaluation of the malignant potential in an apparently clinically benign neoplasm.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Lung / pathology

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883135.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


29. Ahmed M, Bin Yousef H, Greer W, Faraz H, Al Sobhi S, Al Zahrani A, Raef H, Al Ghamdi A, Al Kadhi Y, Al Dayel F: Hurthle cell neoplasm of the thyroid gland. ANZ J Surg; 2008 Mar;78(3):139-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hurthle cell neoplasm of the thyroid gland.
  • BACKGROUND: A clinicopathological analysis and long-term follow up of 32 patients with Hurthle cell neoplasm (HCN) was undertaken to contrast the clinical and histological features between benign versus malignant HCN of thyroid and to examine the effect of treatment on the outcome.
  • RESULTS: Seventeen patients were classified as malignant HCN (MHCN) and 15 as benign HCN (BHCN).
  • Three patients designated MHCN presented with metastases, one with pulmonary metastases and two others with skeletal metastases who developed lung metastases 9-19 months later.
  • The mean tumour size was 4.43 +/- 0.66 cm for MHCN, and 2.57 +/- 0.32 cm for BHCN (P = 0.03).
  • Multicentric tumour foci were evident in five cases (29%) of MHCN but none among the BHCN (P = 0.03).
  • At neck exploration cervical lymph node dissection was carried out in nine MHCN patients with findings of tumour metastases in 33%.
  • CONCLUSION: Features of MHCN consisted of a large tumour size, unequivocal capsular and vascular invasion, multicentric tumour foci, metastatic lymph node deposits in one-third of patients and presence of distant metastasis in a few.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Registries. Retrospective Studies. Risk Assessment. Survival Analysis. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ANZ J Surg. 2008 Mar;78(3):115 [18269467.001]
  • (PMID = 18269475.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


30. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


31. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC: Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol; 2005 Oct;89(10):1270-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PET/CT scans were used as a screening tool at the time of their initial diagnosis.
  • In seven patients (13.4%) PET/CT imaging detected benign lesions in the bone, lung, lymph nodes, colon, and rectum.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Spinal Neoplasms / radiography. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Eye (Lond). 1998;12 ( Pt 6):945-8 [10325992.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] JAMA. 2003 Dec 24;290(24):3199-206 [14693872.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:72S-81S [14736838.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):272-8 [14960647.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2438-44 [15197206.001]
  • [Cites] Br J Ophthalmol. 2004 Aug;88(8):1095-7 [15258035.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):537-40 [15325198.001]
  • [Cites] Cancer. 1974 Oct;34(4):1001-4 [4424282.001]
  • [Cites] Arch Ophthalmol. 1982 Jun;100(6):939-40 [7092632.001]
  • [Cites] Arch Ophthalmol. 1986 Nov;104(11):1624-5 [3778275.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):326S-331S [8440916.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):107-8 [8540843.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2589-95 [9215829.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):201-8 [9261748.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1151-9 [10091801.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • (PMID = 16170114.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC1772897
  •  go-up   go-down


32. Karasavvidou F, Barbanis S, Gravas S, Ioannou M, Oeconomou A, Pappa D, Melekos MD, Koukoulis G: Primary renal epithelioid hemangioendothelioma. Onkologie; 2009 Apr;32(4):203-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Epithelioid hemangioendothelioma (EH) is a rare vascular neoplasm with an unpredictable malignant potential that has been described mainly in soft tissue, liver, and lung.
  • On the basis of the histological and immunohistochemical findings, the diagnosis of EH was made.
  • CONCLUSIONS: Although EH may have a histologically benign appearance and can be treated using a nephron-sparing approach, this neoplasm is potentially malignant urging the need for a long-term follow-up in these patients.
  • [MeSH-major] Abdominal Pain / etiology. Hemangioendothelioma, Epithelioid / complications. Hemangioendothelioma, Epithelioid / diagnosis. Kidney Neoplasms / complications. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19372717.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Piastra M, Ruggiero A, Caresta E, Granone P, Chiaretti A, Polidori G, Riccardi R: Critical presentation of pleuropulmonary blastoma. Pediatr Surg Int; 2005 Mar;21(3):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report two cases of critical presentation of a quite rare lung neoplasm of childhood.
  • Presentation findings were at the extremes of the clinical pattern of this polymorphous neoplasm, ranging from an enormous solid mass causing airway compression and dislocation to an apparently benign cystic lesion discovered because of a tension pneumothorax.
  • Congenital lung cysts, even asymptomatic, should not be underestimated and need elective surgical excision and histologic examination.
  • [MeSH-major] Lung Neoplasms / diagnosis. Pulmonary Blastoma / diagnosis
  • [MeSH-minor] Biopsy. Child, Preschool. Combined Modality Therapy. Cysts / diagnostic imaging. Cysts / pathology. Cysts / therapy. Diagnosis, Differential. Follow-Up Studies. Humans. Lung / diagnostic imaging. Lung / pathology. Pleura / diagnostic imaging. Pleura / pathology. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pleuropulmonary blastoma.
  • Genetic Alliance. consumer health - Blastoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2003 Jan;25(1):78-81 [12544779.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Jun;18(4):259-66 [11400650.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1396-401 [11002236.001]
  • [Cites] Australas Radiol. 2001 Aug;45(3):387-9 [11531773.001]
  • [Cites] Clin Perinatol. 2003 Sep;30(3):481-92 [14533890.001]
  • [Cites] Am Surg. 1993 Mar;59(3):192-6 [8476159.001]
  • [Cites] J Pediatr Surg. 1999 Jul;34(7):1057-9 [10442587.001]
  • [Cites] Med Pediatr Oncol. 1995 Dec;25(6):479-84 [7565313.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Feb;19(2):229-30 [11300091.001]
  • [Cites] J Pediatr. 1996 Feb;128(2):220-4 [8636815.001]
  • [Cites] Ann Thorac Surg. 2002 May;73(5):1594-8 [12022556.001]
  • [Cites] Arch Pediatr. 1994 Oct;1(10 ):919-22 [7842075.001]
  • [Cites] Tumori. 2001 Sep-Oct;87(5):340-2 [11765187.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1516-26 [3048630.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):834-6 [10839886.001]
  • [Cites] Pediatr Pulmonol. 1996 Dec;22(6):408-11 [9016475.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):147-61 [9210721.001]
  • [Cites] J Pediatr Surg. 1996 Jan;31(1):187-9; discussion 190 [8632276.001]
  • (PMID = 15756566.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Glaab R, Turina M, Achermann E, Maurer R, Went P, Schöb O: [Alveolar adenoma--a rare pulmonary mass: case report and review of the literature]. Zentralbl Chir; 2009 Sep;134(5):478-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive histology following thoracoscopic wedge resection showed the distinctive findings of an alveolar adenoma, a very rare benign tumour of the lung of unknown histogenesis.
  • Its histological features, the benign proliferation of alveolar epithelium and septal mesenchyme, allow for its distinction from other benign lesions of the lung.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hemoptysis / etiology. Humans. Lung / pathology. Male. Middle Aged. Phlebography. Pneumonectomy. Thoracoscopy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19757349.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 5
  •  go-up   go-down


35. Seyfarth HJ, Wirtz H, Borte G, Gradistanac T, Gessner C, Hammerschmidt S: [Ultrasound guided transthoracic biopsy - safety and efficaces]. Pneumologie; 2007 Sep;61(9):563-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The biopsy of pulmonary neoplasms localized in close proximity of the thoracic wall and the histological examination of the specimens represent an important diagonstic tool in the work up of benign and malign pulmonary tumours.
  • 13 patients suffered from COPD with a mean residual volume in per cent of total lung capacity of 61.9 +/- 12.6 %.
  • The neoplasm reached the pleura in 41 cases.
  • RESULTS: The histological examination provided the diagnosis in 44 of 46 cases (95.6 %): lung cancer n = 29, other malign tumours n = 9; benign tumours n = 6).
  • Complications, even in patients with structural lung disease are in the range of comparable techniques.
  • [MeSH-major] Biopsy, Needle / methods. Lung Neoplasms / pathology. Lung Neoplasms / ultrasonography. Pulmonary Disease, Chronic Obstructive / pathology. Pulmonary Disease, Chronic Obstructive / ultrasonography. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - COPD.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602390.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Barnett BP, Sheth S, Ali SZ: Cytopathologic analysis of paratracheal masses: a study of 737 cases with clinicoradiologic correlation. Acta Cytol; 2009 Nov-Dec;53(6):672-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the malignant cases, 45 (73%) were metastatic tumors: adenocarcinoma (ACA) 19, small cell carcinoma 12, squamous cell carcinoma (SQCC) 11 and other tumors, from lung 34, esophagus 4 and other sites.
  • Malignant neoplasms from local spread included lung non-small cell carcinoma 6, SQCC 3 and ACA 3, papillary thyroid carcinoma 3 and other 2.
  • The most common diagnosis is a malignant tumor (60%), with metastatic carcinoma (73%) the most common neoplasm (lung ACA the most common primary source).
  • The most common benign entity is a hyperplastic lymph node (24%).
  • Ancillary studies (immunoctyochemistry, fluorescence in situ hybridization and electron microscopy) were helpful and provided definitive diagnosis in 30% of the initially nondiagnostic FNA samples.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014557.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


37. Abe K, Tanaka Y, Takahashi M, Kosuda S, Hayashi K, Tanabe T, Iwasaki Y, Aida S, Kawauchi T, Yamamoto M, Kita T, Kaji T: Pulmonary spread of laryngeal papillomatosis: radiological findings. Radiat Med; 2006 May;24(4):297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laryngeal papillomatosis is a rare benign disease seen in children and young adults.
  • The spread of laryngeal papillomas throughout the respiratory tract occurs rarely; and involvement of the distal bronchi, bronchioles, and lung parenchyma is very rare.
  • The combination of clinical and characteristic radiological features suggests a diagnosis of pulmonary spread of laryngeal papillomatosis.
  • [MeSH-major] Laryngeal Neoplasms / diagnostic imaging. Laryngeal Neoplasms / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / secondary. Papilloma / diagnostic imaging. Papilloma / pathology
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Invasiveness. Radiography

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Otol Rhinol Laryngol. 1973 Sep-Oct;82(5):649-55 [4743394.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Sep;109(9):812-8 [11007082.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1994 Jul;30(1):71-7 [8045697.001]
  • [Cites] AJR Am J Roentgenol. 1979 May;132(5):820-2 [107754.001]
  • [Cites] Respir Med. 1996 Jan;90(1):53-5 [8857327.001]
  • [Cites] Pediatr Pulmonol. 2005 Feb;39(2):185-8 [15532092.001]
  • [Cites] Am J Otolaryngol. 1991 Mar-Apr;12(2):104-12 [1858973.001]
  • [Cites] N Engl J Med. 1987 Oct 1;317(14):873-8 [2442608.001]
  • [Cites] Pathol Int. 2000 May;50(5):431-9 [10849335.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2003 Oct;67(10):1117-21 [14550967.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jul-Aug;18(4):640-2 [8040453.001]
  • [Cites] Cancer. 1959 Jan-Feb;12(1):117-26 [13626216.001]
  • [Cites] Genitourin Med. 1997 Feb;73(1):63-5 [9155559.001]
  • [Cites] Eur Respir J. 2001 Apr;17 (4):830-1 [11401080.001]
  • [Cites] Am Rev Respir Dis. 1963 Dec;88:839-46 [14087237.001]
  • [Cites] Am J Pathol. 1932 May;8(3):333-338.1 [19970022.001]
  • [Cites] South Med J. 1999 Oct;92(10):1013-6 [10548177.001]
  • [Cites] Chest. 2000 Oct;118(4):1210-4 [11035700.001]
  • [Cites] Chest. 1994 Jun;105(6):1887-8 [8205902.001]
  • [Cites] AJR Am J Roentgenol. 1985 Apr;144(4):687-94 [3872022.001]
  • [Cites] J Comput Assist Tomogr. 2002 Jan-Feb;26(1):5-12 [11801898.001]
  • [Cites] Radiology. 1968 Apr;90(4):654-60 [5640802.001]
  • (PMID = 16958405.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Akin M, Irkorucu O, Koksal H, Gonul II, Gultekin S, Kurukahvecioglu O, Anadol AZ, Tekin E: Phyllodes tumor of the breast; a case series. Bratisl Lek Listy; 2010;111(5):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the breast; a case series.
  • BACKGROUND: Phyllodes tumor (PT) is a rare neoplasm comprising less than 1% of all breast tumors.
  • Its clinical spectrum ranges from a benign and locally recurrent form of behavior to malignant and metastatic forms.
  • All cases were histologically examined by an experienced breast pathologist, and tumors were classified as benign, borderline malignant or malignant according to standard histological criteria.
  • RESULTS: The median age at diagnosis was 45.5 years (range: 21-69 years).
  • Seven (70%) of 10 tumors were benign and 3 (30%) were malignant.
  • The median tumor size was 29 mm (range: 12-80 mm).
  • Only one patient had lung metastasis.
  • The patient with lung metastasis was treated with doxorubicine but died one year after the operation.
  • CONCLUSION: PT is a rare neoplasm of the breast.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568416.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


39. Korpershoek E, Loonen AJ, Corvers S, van Nederveen FH, Jonkers J, Ma X, Ziel-van der Made A, Korsten H, Trapman J, Dinjens WN, de Krijger RR: Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. J Pathol; 2009 Mar;217(4):597-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phaeochromocytomas (PCCs) are neuro-endocrine tumours of the adrenal medulla that are usually benign, but approximately 10% of patients develop metastases.
  • In 6 of 17 investigated mice, histological and immunohistochemical evidence was obtained for the presence of PCC lung metastases.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Disease Models, Animal. Lung Neoplasms / secondary. Neoplasm Proteins / genetics. PTEN Phosphohydrolase / genetics. Pheochromocytoma / secondary


40. Corapçioğlu F, Kargi A, Olgun N, Ozer E, Olguner M, Sarialioğlu F: Inflammatory myofibroblastic tumor of the ileocecal mesentery mimicking abdominal lymphoma in childhood: report of two cases. Surg Today; 2005;35(8):687-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the ileocecal mesentery mimicking abdominal lymphoma in childhood: report of two cases.
  • An inflammatory myofibroblastic tumor is an uncommon benign tumor located in various organs that can be misdiagnosed as a malignant neoplasm.
  • We herein present two patients with ileocecal inflammatory myofibroblastic tumors.
  • The presumptive diagnosis was Burkitt's lymphoma.
  • The histopathological diagnosis was inflammatory myofibroblastic tumor.
  • Inflammatory myofibroblastic tumor is a rare pseudosarcomatous clinical and pathological entity.
  • Although this tumor is more commonly reported in the lung, it can be detected in extrapulmonary sites, including the mesentery.
  • Because the choice of treatment for this tumor is conservative surgery, an accurate preoperative analysis is important to avoid any unnecessary aggressive surgical intervention or other therapeutic approaches.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Lymphoma / diagnosis. Neoplasms, Muscle Tissue / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Cecum. Diagnosis, Differential. Female. Humans. Ileum. Male. Mesentery

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 1998;28(11):1172-4 [9851627.001]
  • [Cites] J Pediatr Surg. 2001 Jun;36(6):908-12 [11381424.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):538-46 [2239820.001]
  • [Cites] Cancer. 1993 Sep 15;72 (6):2042-8 [8364883.001]
  • [Cites] Surg Today. 2003;33(9):714-7 [12928854.001]
  • [Cites] N Engl J Med. 1984 Mar 29;310(13):839-45 [6700673.001]
  • [Cites] J Pediatr Surg. 1996 Jun;31(6):840-2 [8783118.001]
  • [Cites] Surg Today. 2000;30(10 ):942-6 [11059739.001]
  • [Cites] Surg Today. 1993;23(3):246-50 [8467177.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1234-41 [2400974.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):807-14 [2841219.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1146-56 [1746682.001]
  • (PMID = 16034552.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


41. Chen G, Liu XY, Wang Z, Liu FY: Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg; 2010 Mar;37(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer.
  • OBJECTIVE: Mediastinal lymph node metastasis (N2) is a key prognostic factor for lung carcinoma.
  • This study was undertaken to investigate the relationship between vascular endothelial growth factor C (VEGF-C) expression and postoperative early recurrence in patients with N2 non-small-cell lung cancer.
  • METHODS: Cancer tissue samples from 92 patients with pN2 non-small-cell lung cancer and benign lung disease tissues samples from 30 patients were examined by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry assays to detect VEGF-C expression.
  • All patients with N2 disease were evaluated within 1 year after surgery to detect early tumour recurrence.
  • Cox regression analysis was performed to determine the risk factors of postoperative early recurrence of N2 lung cancer.
  • RESULTS: VEGF-C mRNA expression was observed in 64 (70%) pN2 lung cancer tissues, but was not found in benign lung disease tissues.
  • The main pattern was distant recurrence, and the most frequent sites were the brain and lung.
  • Cox regression analysis revealed that positive VEGF-C expression in tumours (hazard ratio (HR)=2.523, P=0.037) was an independent risk factor of postoperative early recurrence of N2 lung cancer.
  • CONCLUSIONS: VEGF-C expression was high in N2 lung cancer, with significant correlation to postoperative early recurrence.
  • About one-half of the patients with N2 non-small-cell lung cancer would develop recurrence disease within 1 year after surgery, frequently with mediastinal nodes, brain or lung metastases.
  • VEGF-C might be a predictor of postoperative early recurrence in patients with N2 non-small-cell lung cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor C / biosynthesis
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19758816.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


42. Hatori M, Watanabe M, Kotake H, Kokubun S: Chondrosarcoma of the ring finger: a case report and review of the literature. Tohoku J Exp Med; 2006 Mar;208(3):275-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Enchondromas are the most common benign cartilaginous bone tumors arising in the medullary cavity of the small bones of the hand.
  • The findings of cortical irregular thickening by plain radiography and computed tomography and soft tissue extension by magnetic resonance imaging suggested the tumor was chondrosarcoma rather than a common enchondroma.
  • Histological examination revealed that the tumor was composed of polygonal cells with eosinophilic cytoplasm proliferating in the chondromatous matrix with partially myxoid changes.
  • Nuclear irregularity, binucleated cells, bone permeation and encasement were observed and the tumor was diagnosed as grade 2 chondrosarcoma.
  • The tumor recurred five months after surgery.
  • At two years after surgery, the patient was free from recurrence or lung metastasis.
  • In conclusion, details of radiological as well as pathological findings are essential for differential diagnosis between benign enchondroma and chondrosarcoma in the hand.
  • [MeSH-minor] Aged, 80 and over. Chondroma / diagnosis. Diagnosis, Differential. Disease-Free Survival. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498237.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Yadav RK, Sen R, Agarwal S, Aggarwal S: CT-guided FNAC of intrathoracic mass lesions--a study among 35 patients. J Indian Med Assoc; 2010 Sep;108(9):571-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A correct diagnosis could be made in 31 patients amounting to an accuracy of 88.57%.
  • There were 28/35 patients (80%) with malignancies, and only 3/35 with benign inflammatory lesions.
  • CT-guided FNAC is accurate, safe and minimally invasive procedure for diagnosis of intrathoracic mass lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma / diagnosis. Lung Neoplasms / diagnosis. Mediastinal Neoplasms / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21510529.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


44. Chong S, Lee KS: Spectrum of findings and usefulness of integrated PET/CT in patients with known or suspected neuroendocrine tumors of the lung. Cancer Imaging; 2007;7:195-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of findings and usefulness of integrated PET/CT in patients with known or suspected neuroendocrine tumors of the lung.
  • Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) has been known to increase diagnostic accuracy in differentiating benign and malignant lung lesions and to improve identification of lymph node and extrathoracic metastasis in pulmonary neoplasms.
  • In this review, the authors describe the spectrum of integrated PET/CT findings on neuroendocrine (NE) tumors of the lung.
  • We also demonstrate the usefulness of this imaging modality in patients with known or suspected NE tumors of the lung.
  • [MeSH-major] Lung Neoplasms / radionuclide imaging. Neuroendocrine Tumors / radionuclide imaging. Positron-Emission Tomography. Tomography, Emission-Computed
  • [MeSH-minor] Fluorodeoxyglucose F18. Humans. Neoplasm Staging. Prognosis. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jan;30(1):78-84 [12483413.001]
  • [Cites] Am J Clin Oncol. 2004 Apr;27(2):164-71 [15057156.001]
  • [Cites] Clin Nucl Med. 2004 Nov;29(11):752-3 [15483502.001]
  • [Cites] Cancer Chemother Rep 3. 1973 Mar;4(2):31-42 [4580860.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):529-53 [1709558.001]
  • [Cites] AJR Am J Roentgenol. 2007 May;188(5):1223-31 [17449764.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1369-73 [9574618.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):934-44 [9706973.001]
  • [Cites] Radiographics. 1999 May-Jun;19(3):707-36 [10336200.001]
  • [Cites] Radiographics. 2006 Jan-Feb;26(1):41-57; discussion 57-8 [16418242.001]
  • [Cites] J Intern Med. 2006 Dec;260(6):545-50 [17116005.001]
  • [Cites] Chest. 1997 Jun;111(6):1718-23 [9187199.001]
  • (PMID = 18055292.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC2151326
  •  go-up   go-down


45. Carnochan FM, Walker WS: Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients. Eur J Cardiothorac Surg; 2009 May;35(5):781-4; discussion 784-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography may underestimate the extent of thoracic disease in lung cancer patients.
  • OBJECTIVE: Although widely utilised in the staging of lung cancer various studies have questioned whether the accuracy of this staging modality is sufficient to replace conventional invasive staging techniques.
  • We have therefore reviewed our experience in order to assess the accuracy of PET CT as an intrathoracic staging tool for non-small cell lung cancer (NSCLC).
  • Five (2.5%) resections were benign despite avid FDG uptake, and 6 (3%) were malignant despite a negative scan.
  • Twelve (6%) of patients were under-staged regarding chest wall and mediastinal invasion, and 10 (5%) patients had metastatic nodules in the lung (T4) not detected by PET CT.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Errors. Female. Humans. Lymphatic Metastasis. Male. Mediastinoscopy. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19272791.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Kushibe K, Kawaguchi T, Nishimoto Y, Takahama M, Tojo T, Taniguchi S: Operative indications for lung cancer with satellite lesions. Asian Cardiovasc Thorac Ann; 2006 Aug;14(4):316-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Operative indications for lung cancer with satellite lesions.
  • In deciding the surgical treatment for lung cancer, it is important to differentiate between a small satellite lesion that is probably benign, a pulmonary metastatic lesion, or a double cancer.
  • The operative indications for lung cancer with small satellite lesions detected on preoperative helical computed tomography were retrospectively examined.
  • A definitive diagnosis was made by follow-up computed tomography in 3 of 19 ipsilateral lesions and in 9 of 24 contralateral lesions.
  • The final diagnosis of the satellite lesions was malignant in 13 and benign in 30.
  • Two patients with stage IIb and IIIb disease on clinical staging of the main tumor had pulmonary metastases.
  • Patients with clinical stage I disease had a higher probability that the small lesions were benign or double cancers than those with advanced disease beyond clinical stage I.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Solitary Pulmonary Nodule / pathology. Solitary Pulmonary Nodule / surgery
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868106.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB: Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol; 2008 May 21;14(19):3074-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to examine the promoter methylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal disease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls.
  • A paired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postoperative serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent surgical therapy.
  • RESULTS: The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01).
  • The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples.
  • The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / blood. Promoter Regions, Genetic. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2000 Dec;30(3):211-4 [11147802.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1225-30 [17914577.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7034-8 [11585730.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3792-5 [12032847.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7277-82 [12370819.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):623-8 [12448005.001]
  • [Cites] J Pathol. 2003 May;200(1):23-31 [12692837.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):207-16 [12706879.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):99-105 [12706863.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8125-36 [14603253.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3682-90 [15867363.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):576-83 [15948711.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1293-6 [16001680.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5205-10 [16051962.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7653-9 [16140931.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7630-4 [16007118.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):339-46 [16139926.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35669-72 [10998413.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Lung Cancer. 2007 May;56(2):289-94 [17267069.001]
  • [Cites] BMC Cancer. 2007;7:120 [17608924.001]
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):242-51 [17652530.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • (PMID = 18494062.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2712178
  •  go-up   go-down


48. Ozolek JA, Hunt JL: Tumor suppressor gene alterations in respiratory epithelial adenomatoid hamartoma (REAH): comparison to sinonasal adenocarcinoma and inflamed sinonasal mucosa. Am J Surg Pathol; 2006 Dec;30(12):1576-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppressor gene alterations in respiratory epithelial adenomatoid hamartoma (REAH): comparison to sinonasal adenocarcinoma and inflamed sinonasal mucosa.
  • Respiratory epithelial adenomatoid hamartoma (REAH) is an unusual benign sinonasal glandular proliferation.
  • REAH is not considered a neoplasm, although, no molecular evidence exists to support or refute this possibility.
  • DNA was extracted and polymerase chain reaction performed using fluorescently labeled primers flanking known tumor suppressor genes on chromosomes 9p (CDKN2/p16), 11p (H-ras), 17p (p53), and 18q (DCC/DPC4).
  • The loss of heterozygosity (LOH) ratio was calculated as the allele ratio from tumor tissue divided by the allele ratio from normal tissue.
  • Appreciable allelic loss within REAH suggests the possibility that REAH may be a benign neoplasm rather than a hamartoma.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, Tumor Suppressor. Hamartoma / genetics. Loss of Heterozygosity. Lung Diseases / genetics. Paranasal Sinus Neoplasms / genetics. Sinusitis / genetics


49. Zhang YX, Chen HL, Ye B, Yang F, Yu LY: [Study on expression and methylation of caveolin 1 gene in non-small cell lung cancers]. Zhonghua Bing Li Xue Za Zhi; 2008 May;37(5):300-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on expression and methylation of caveolin 1 gene in non-small cell lung cancers].
  • OBJECTIVE: To study the methylation of CpG islands in the promoter region, expression of caveolin 1 (Cav-1) gene and their clinical significance in non-small cell lung cancers (NSCLC).
  • METHODS: Immunohistochemistry and quanta Qd600 staining were used to detect the expression of Cav-1 in tissues from benign lung lesions (n = 17) and NSCLC (n = 123).
  • Amongst the NSCLC group, there was no statistically significant difference in Cav-1 protein expression in different histologic types (P = 0.552) and tumor grades (P = 0.160).
  • On the other hand, Cav-1 protein immunoreactivity was remarkably higher in advanced tumor stage: 72.7% in stage III A + III B, compared with 9.4% in stage I A + I B and 38.3% in stage II A + II B (P = 0.001).
  • DNA from 40 NSCLC cases with negative Cav-1 protein expression and 12 cases of peritumoral lung tissues were extracted.
  • Methylation in the promoter region of Cav-1 gene was not detected in lung cancer or peritumoral tissues.
  • CONCLUSIONS: High expression of Cav-1 protein is respected of the aggressive clinical behavior and advanced tumor stage.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Caveolin 1 / metabolism. Gene Regulatory Networks / genetics. Lung Neoplasms / genetics
  • [MeSH-minor] Aged. DNA Methylation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging / methods. Somatoform Disorders

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956646.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


50. Shen R, Pan S, Qi S, Lin X, Cheng S: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun; 2010 Apr 16;394(4):1047-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High levels of SOX4 expression have been found in a variety of human cancers, such as lung, brain and breast cancers.
  • The SOX4 expression was detected using immunohistochemical staining and semi-quantitative RT-PCR, and our results showed that SOX4 was up-regulated in gastric cancer compared to benign gastric tissues.
  • [MeSH-minor] Apoptosis / genetics. DNA Methylation. Down-Regulation. Gene Expression Profiling. Humans. Neoplasm Metastasis. Prognosis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20331975.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Mirn129 microRNA, human; 0 / SOX4 protein, human; 0 / SOXC Transcription Factors
  •  go-up   go-down


51. Wu GC, Hu HC, Shi MH: [Expression and clinical significance of a disintegrin and metalloprotease 8 (ADAM8) and epidermal growth factor receptor (EGFR) in non-small cell lung cancer]. Ai Zheng; 2008 Aug;27(8):874-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of a disintegrin and metalloprotease 8 (ADAM8) and epidermal growth factor receptor (EGFR) in non-small cell lung cancer].
  • BACKGROUND & OBJECTIVE: Up-regulation of a disintegrin and metalloprotease 8 (ADAM8) is correlated with genesis, progression, invasion, and metastasis of tumors.
  • However, the expression of ADAM8, especially its correlation to epidermal growth factor receptor (EGFR), has seldom been reported in non-small cell lung cancer (NSCLC).
  • METHODS: Expressions of ADAM8 and EGFR in 49 specimens of NSCLC, 28 specimens of adjacent lung tissues and 13 specimens of benign lung tissues were detected using tissue microarray (TMA) and immunohistochemistry (IHC).
  • The positive rates of ADAM8 and EGFR were significantly higher in NSCLC than in adjacent lung tissues and benign lung tissues (73.5% vs. 10.7% and 15.4%, 69.4% vs. 14.2% and 23.1%, P<0.01).
  • [MeSH-major] ADAM Proteins / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Membrane / metabolism. Cytoplasm / metabolism. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Up-Regulation


52. Rodriguez FJ, Aubry MC, Tazelaar HD, Slezak J, Carney JA: Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol; 2007 Dec;31(12):1844-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma.
  • The Carney triad is the clinical association of gastric stromal sarcomas, pulmonary cartilaginous tumors, and extra-adrenal paragangliomas.
  • The pulmonary tumors are its second commonest component and have been misinterpreted clinically and pathologically as metastases from the gastric tumors and pulmonary cartilaginous hamartomas, respectively.
  • Forty-two patients with pulmonary cartilaginous tumors as a component of Carney triad were identified.
  • A subgroup of 41 tumors from the latter was compared with those in a group of pulmonary cartilaginous hamartomas.
  • Their pulmonary neoplasm(s) were usually asymptomatic, often multiple, well circumscribed, medium-sized (mean diameter=2.8 cm), and composed almost exclusively of cartilage and bone surrounded by a fibrous pseudocapsule.
  • None of the tumors metastasized or was fatal.
  • The pulmonary neoplasms in the Carney triad are well-differentiated benign cartilaginous tumors that are best designated as chondromas.
  • [MeSH-major] Chondroma / pathology. Hamartoma / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Paraganglioma, Extra-Adrenal / pathology

  • Genetic Alliance. consumer health - Chondroma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043038.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Balduyck B, Lauwers P, Govaert K, Hendriks J, De Maeseneer M, Van Schil P: Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report. J Thorac Oncol; 2006 Jul;1(6):588-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report.
  • Tumor-associated hypoglycemia as a paraneoplastic phenomenon is a well-known entity and is referred to as Doege-Potter syndrome.
  • On transthoracic puncture, a tumor of pleural origin was diagnosed.
  • This tumor, presenting as a large, well-circumscribed encapsulated mass, was removed by thoracotomy.
  • On pathologic examination, the diagnosis of a solitary fibrous tumor with benign characteristics was made.
  • Solitary fibrous tumors are localized tumors of the pleura with an unpredictable behavior.
  • [MeSH-minor] Aged. Biopsy, Needle. Bronchoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Radiography, Thoracic. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Potter syndrome.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409923.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Valentí V, López-Pousa A, Gonzalez Y, Farré N: Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature. J Craniofac Surg; 2005 May;16(3):452-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation-induced sarcomas are uncommon tumors that are diagnosed by meeting some diagnostic criteria.
  • The authors have found in the literature 30 cases of mandibular radiation-induced osteogenic sarcomas, most of them secondary to treatment of benign lesions, none of them secondary to treatment of a laryngeal cancer, as was seen in their case.
  • [MeSH-minor] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / radiotherapy. Fatal Outcome. Humans. Laryngeal Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915114.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Awonuga AO, Rotas M, Imudia AN, Choi C, Khulpateea N: Recurrent benign metastasizing leiomyoma after hysterectomy and bilateral salpingo-oophorectomy. Arch Gynecol Obstet; 2008 Oct;278(4):373-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent benign metastasizing leiomyoma after hysterectomy and bilateral salpingo-oophorectomy.
  • BACKGROUND: Benign uterine leiomyomas are sometimes found in association with benign smooth muscle tumors outside the confines of the uterus and are given the name benign metastasizing leiomyomas (BML).
  • PATIENTS: Our patients, presented with multiple abdominal masses 6 years after their initial surgery for benign leiomyoma.
  • At exploratory laparotomy multiple benign leiomyomas were resected, and in one case a 2.2 cm leiomyoma was also resected from the left lower lobe of the lung.
  • RESULTS: Pathology revealed benign leiomyomas with no cytological atypia and a mitotic count of <5 per 10 high power fields (hpf).
  • CONCLUSION: Benign metastasizing leiomyoma rarely follow TAH/BSO in patients with uterine myoma and estrogen replacement therapy may play a role in such occurrence.
  • Despite surgery to remove these tumors, they can still recur; therefore, there is need for prolonged surveillance in such patients after resection.
  • [MeSH-major] Leiomyomatosis / pathology. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259767.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Bu LN, Yang SY, Du J, Nan YD, Lin XL, Zheng HD, Huo SF, Shang WL, Liu YF: [Application of liquid chip-mass spectrometry technology for screening serum biomarker proteins in lung squamous cell carcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Jun 23;89(24):1662-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of liquid chip-mass spectrometry technology for screening serum biomarker proteins in lung squamous cell carcinoma].
  • OBJECTIVE: To screen the serum biomarker proteins of lung squamous cell carcinoma (SCCs) by liquid chip-mass spectrometry technology.
  • METHODS: All serum samples, including 34 SCCs, 46 benign lung diseases (BLDs) and 44 healthy individuals, were analyzed by CLINPROT system in order to study the serum protein expression profiles.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Case-Control Studies. Female. Humans. Male. Mass Spectrometry. Middle Aged. Molecular Sequence Data. Neoplasm Staging. Oligonucleotide Array Sequence Analysis


57. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • Nongynecological tumors expressing L1 comprised malignant melanoma, colon adenocarcinoma positive to chromogranin, clear-cell adenocarcinoma of the urinary bladder, pheochromocytoma, small cell lung carcinoma, and tumors of the nervous system.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


58. Antic T, Kapur U, Vigneswaran WT, Oshima K: Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance. Arch Pathol Lab Med; 2005 Oct;129(10):1334-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory sarcomatoid carcinoma: a case report and discussion of a malignant tumor with benign appearance.
  • Inflammatory sarcomatoid carcinoma is an aggressive tumor with an unusually benign appearance.
  • We report the case of a 65-year-old man with a history of inoperable poorly differentiated carcinoma of the right lung, for which he had received chemoradiotherapy.
  • A new solitary mass was discovered 4 years later in the left lung on surveillance computed tomography.
  • In contrast to sarcomatoid carcinomas, this case highlights the deceptively benign appearance of inflammatory sarcomatoid carcinoma.
  • This leads us to concur with the recommendation to exercise caution when attempting the diagnosis of apparently benign lesions on intraoperative frozen section in patients with high clinical suspicion of malignancy.
  • [MeSH-major] Carcinosarcoma / pathology. Lung Neoplasms / pathology. Plasma Cell Granuloma, Pulmonary / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Bronchiolitis Obliterans / diagnosis. Diagnosis, Differential. Humans. Lymphomatoid Granulomatosis. Male. Neoplasm Invasiveness. Neoplasms, Second Primary. Pneumonia / diagnosis. Sarcoma / diagnosis. Sarcoma / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16196527.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 16
  •  go-up   go-down


59. Way TW, Sahiner B, Chan HP, Hadjiiski L, Cascade PN, Chughtai A, Bogot N, Kazerooni E: Computer-aided diagnosis of pulmonary nodules on CT scans: improvement of classification performance with nodule surface features. Med Phys; 2009 Jul;36(7):3086-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided diagnosis of pulmonary nodules on CT scans: improvement of classification performance with nodule surface features.
  • The purpose of this work is to develop a computer-aided diagnosis (CAD) system to differentiate malignant and benign lung nodules on CT scans.
  • A data set of 256 lung nodules (124 malignant and 132 benign) from 152 patients was used in this study.
  • In addition to morphological and texture features, the authors designed new nodule surface features to characterize the lung nodule surface smoothness and shape irregularity.
  • A similar experiment performed on the data set restricted to primary cancers and benign nodules, excluding the metastatic cancers, also resulted in an improved test A(z), though the improvement did not reach statistical significance (p = 0.07).
  • This study demonstrated that the authors' proposed segmentation and feature extraction techniques are promising for classifying lung nodules on CT images.
  • [MeSH-major] Diagnosis, Computer-Assisted. Image Interpretation, Computer-Assisted / methods. Lung Neoplasms / diagnosis. Lung Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Age Factors. Algorithms. Area Under Curve. Discriminant Analysis. Female. Humans. Imaging, Three-Dimensional. Male. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / diagnostic imaging. Neoplasm Metastasis / pathology. Principal Component Analysis. Sex Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Phys. 1999 Dec;26(12):2654-68 [10619251.001]
  • [Cites] Phys Med Biol. 2008 Mar 7;53(5):1295-312 [18296763.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):25-32 [11139308.001]
  • [Cites] Radiology. 2002 Mar;222(3):773-81 [11867800.001]
  • [Cites] Chest. 2002 Jul;122(1):15-20 [12114333.001]
  • [Cites] Radiology. 2003 Mar;226(3):756-61 [12601181.001]
  • [Cites] Med Phys. 2003 Mar;30(3):387-94 [12674239.001]
  • [Cites] Radiology. 2003 May;227(2):469-74 [12732700.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2535-42 [12815140.001]
  • [Cites] Med Phys. 2003 Jun;30(6):1188-97 [12852543.001]
  • [Cites] AJR Am J Roentgenol. 2004 Nov;183(5):1209-15 [15505279.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):565-70 [6486554.001]
  • [Cites] Radiology. 1993 Feb;186(2):405-13 [8421743.001]
  • [Cites] Radiology. 1995 Sep;196(3):823-9 [7644650.001]
  • [Cites] Radiology. 1996 Dec;201(3):798-802 [8939234.001]
  • [Cites] Med Phys. 1998 Apr;25(4):516-26 [9571620.001]
  • [Cites] Lancet. 1998 Apr 25;351(9111):1242-5 [9643744.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Med Phys. 1999 Jun;26(6):880-8 [10436888.001]
  • [Cites] Radiology. 2005 Apr;235(1):259-65 [15695622.001]
  • [Cites] Acad Radiol. 2005 May;12(5):570-5 [15866129.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Sep;24(9):1138-50 [16156352.001]
  • [Cites] Med Phys. 2005 Aug;32(8):2443-54 [16193773.001]
  • [Cites] Radiology. 2006 Apr;239(1):34-49 [16567482.001]
  • [Cites] Med Phys. 2006 Jul;33(7):2323-37 [16898434.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1822-4 [17065645.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1509-22 [10947254.001]
  • (PMID = 19673208.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093517; United States / NCI NIH HHS / CA / CA93517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2832039
  •  go-up   go-down


60. Schmidt B, Weickmann S, Witt C, Fleischhacker M: Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci; 2008 Aug;1137:207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease.
  • We isolated cell-free DNA from plasma, serum, and bronchial lavage supernatants from 33 lung cancer patients and 27 patients with a benign lung disease.
  • Our results led us to conclude that this method is not useful in a diagnostic setting and is not able to differentiate between lung cancer patients and patients with a benign lung disease.
  • [MeSH-major] Biomarkers, Tumor. DNA / blood. DNA, Neoplasm / blood. Lung Diseases. Lung Neoplasms
  • [MeSH-minor] Aged. Aged, 80 and over. Bronchoalveolar Lavage Fluid / chemistry. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837948.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


61. Hoshino S, Furukawa M, Aragane K, Horimoto M, Suzuki K, Shiono H, Minami M, Okumura M, Kijima T, Kawase I: Successful multimodal treatment in a patient with thymoma accompanied by hepatic metastasis. J Thorac Oncol; 2008 Jan;3(1):98-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite a benign histologic appearance, thymomas have metastatic potential.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Biopsy, Needle. Catheter Ablation / methods. Cisplatin / therapeutic use. Combined Modality Therapy. Drug Administration Schedule. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Middle Aged. Myasthenia Gravis / drug therapy. Myasthenia Gravis / pathology. Neoplasm Metastasis. Neoplasm Staging. Positron-Emission Tomography. Thymectomy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166848.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M: A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev; 2007 Feb 15;21(4):379-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.
  • BRaf(CA) mice infected with an Adenovirus expressing Cre recombinase developed benign lung tumors that only rarely progressed to adenocarcinoma.
  • Moreover, BRaf(VE)-induced lung tumors were prevented by pharmacological inhibition of MEK1/2.
  • Consistent with Ink4a/Arf and TP53 tumor suppressor function, BRaf(VE) expression combined with mutation of either locus led to cancer progression.


63. Li Y, Yang Z: [Research development of MDCT perfusion imaging on solitary pulmonary nodules]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Oct;25(5):1222-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differentiation between benign and malignant solitary pulmonary nodules remains significant and a challenge to thoracic radiologists.
  • Recently, MDCT perfusion imaging has sparked new interest in the noninvasive assessment of pulmonary neoplasm.
  • [MeSH-major] Lung / blood supply. Lung Neoplasms / radiography. Tomography, Spiral Computed / methods. Tuberculosis, Pulmonary / radiography
  • [MeSH-minor] Diagnosis, Differential. Humans. Lung Diseases / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024481.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  •  go-up   go-down


64. Li C, Liu ZS, Du XM, He L, Chen J, Wang W, Sun F, Du F, Luo ZG, Xue ZL, Zhao Y, Zhou CW: Clinical value of whole-body magnetic resonance diffusion weighted imaging on detection of malignant metastases. Chin Med Sci J; 2009 Jun;24(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-six patients with malignant tumors underwent WB-DWI examinations between April 2007 and August 2007 in our hospital.
  • For the assessment of the diagnostic capability of WB-DWI, WB-DWI were compared with CT for demonstrating mediastinal lymph node metastases and lung metastases, and with conventional MRI for demonstrating metastases in other locations.
  • RESULTS: WB-DWI demonstrated 143 focuses, 14 of which were diagnosed to be benign lesions in routine imaging.
  • The number of bone metastases depicted on WB-DWI and routine imaging was 85 and 86; lymph node metastases was 17 and 18; liver metastases was 14 and 14; lung metastases was 4 and 8; and brain metastases was 6 and 8, respectively.
  • WB-DWI failed to detect 12 metastatic lesions including 3 osteoplastic bone metastases, 4 lung metastases, 3 mediastinal lymph node metastases, and 2 brain metastases.
  • WB-DWI had higher detection rates for metastatic lesions in liver, bone, and lymph nodes than those in lung and brain (chi2=30, P<0.001).
  • The limitations of WB-DWI might be had high false-positive rate and low efficiency in detecting mediastinal lymph node, brain, and lung metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618609.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. Rom WN, Goldberg JD, Addrizzo-Harris D, Watson HN, Khilkin M, Greenberg AK, Naidich DP, Crawford B, Eylers E, Liu D, Tan EM: Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer; 2010 May 26;10:234
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers.
  • BACKGROUND: Sera from lung cancer patients contain autoantibodies that react with tumor associated antigens (TAAs) that reflect genetic over-expression, mutation, or other anomalies of cell cycle, growth, signaling, and metabolism pathways.
  • METHODS: We performed immunoassays to detect autoantibodies to ten tumor associated antigens (TAAs) selected on the basis of previous studies showing that they had preferential specificity for certain cancers.
  • Sera examined were from lung cancer patients (22); smokers with ground-glass opacities (GGOs) (46), benign solid nodules (55), or normal CTs (35); and normal non-smokers (36).
  • Logistic regression models based on the antibody biomarker levels among the high risk and lung cancer groups were developed to identify the combinations of biomarkers that predict lung cancer in these cohorts.
  • CONCLUSION: A pattern of autoantibody reactivity to TAAs may distinguish patients with lung cancer versus smokers with normal CTs, stable solid nodules, ground glass opacities, or normal healthy never smokers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9 [11504947.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Nov 15;172(10):1308-14 [16109979.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):3085-92 [11712815.001]
  • [Cites] J Clin Invest. 2001 Nov;108(10):1411-5 [11714730.001]
  • [Cites] Chest. 2002 May;121(5):1464-7 [12006429.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2298-305 [12114434.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Mar 1;173(5):535-9 [16339918.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3461-7 [17409457.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):513-9 [17409910.001]
  • [Cites] Thorax. 2008 Mar;63(3):228-33 [17932110.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5060-6 [18794547.001]
  • [Cites] Clin Immunol. 2001 Aug;100(2):149-56 [11465943.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):5006-15 [12118381.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):372-8 [12402307.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43 [12582023.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):297-301 [12609568.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1652-6 [12670919.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):285-90 [12893076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42 [14573703.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5120-6 [14613989.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):403-8 [6292117.001]
  • [Cites] Am J Pathol. 1992 Oct;141(4):881-6 [1415481.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2419-26 [8227358.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4529-36 [8643438.001]
  • [Cites] Hepatology. 1997 Jan;25(1):75-80 [8985268.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1767-75 [9816128.001]
  • [Cites] Ann Neurol. 1999 Feb;45(2):162-7 [9989617.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):313-23 [15541816.001]
  • [Cites] Prostate. 2005 May 15;63(3):252-8 [15538718.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2714-20 [15987920.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7102-10 [16103059.001]
  • [Cites] BMC Cancer. 2005;5:110 [16117833.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):1079-85 [16142326.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • (PMID = 20504322.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / T32 ES007267; United States / NCRR NIH HHS / RR / M01RR-00096; United States / NCI NIH HHS / CA / U01CA86137; United States / NCI NIH HHS / CA / U01 CA086137-11; United States / NCI NIH HHS / CA / CA086137-11; United States / NIEHS NIH HHS / ES / T32 ES007267-18; United States / NIEHS NIH HHS / ES / ES007267-18; United States / NCI NIH HHS / CA / CA 56956; United States / NCI NIH HHS / CA / U01 CA086137
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies
  • [Other-IDs] NLM/ PMC2885364
  •  go-up   go-down


66. Novikov DV, Belova TV, Pegov RG, Aliasova AA, Morozova PN, Kniazev DI, Kalugin AV, Kontorshchikova KN, Baryshnikov AIu, Novikov VV: [Detection rate of MAGE-A1-A6 mRNA in the peripheral blood of cancer patients]. Klin Lab Diagn; 2009 Apr;(4):25-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mRNA expression of 6 MAGE-A (MAGE-A1-A6) antigens by the tumor focal cells and cancer cells circulating in blood was studied in solid malignant and benign neoplasms.
  • MAGE- A1-A6 mRNA expression was detected in the tumor focal cells in more than 90% of cases of cancer of the breast, lung, and stomach and melanoma cell lines.
  • The detection rate of peripheral blood MAGE-A1-A6-positive tumor cells was 95% in lung cancer, 53% in corpus uteri cancer, 67% in gastric cancer, 63% in breast cancer, 33% in melanoma, and 42% in uterine myoma.
  • [MeSH-major] Biomarkers, Tumor / blood. Neoplastic Cells, Circulating / metabolism. RNA, Messenger / blood
  • [MeSH-minor] Antigens, Neoplasm / blood. Female. Humans. Melanoma-Specific Antigens. Neoplasm Proteins / blood. Neoplasms / blood

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514330.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MAGEA3 protein, human; 0 / MAGEA4 protein, human; 0 / MAGEA6 protein, human; 0 / Mage-a2 antigen; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


67. Kumar R, Alavi A: Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma. Curr Opin Oncol; 2005 Mar;17(2):154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis is linked directly to the initial stage at the time of diagnosis.
  • Early diagnosis and accurate disease staging is important for appropriate treatment planning.
  • Despite the overall superiority of FDG-PET in the detection of melanoma metastases, it has limitations in detection of early-stage disease (stage I-II), small lung nodules, and brain metastases.
  • False-positive FDG-PET results are due to postsurgical inflammation, other inflammatory lesions, and some benign tumors.
  • [MeSH-minor] Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725921.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 37
  •  go-up   go-down


68. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS: Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther; 2009 May;8(10):907-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues.
  • The Cub and Sushi Multiple Domains-1 (CSMD1) is a tumor suppressor gene on 8p23.2, where allelic loss is both frequent and associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC).
  • To understand the extent of CSMD1 aberrations in vivo, we characterized 184 primary tumors from the head and neck, lung, breast and skin for gene copy number and analyzed expression in our HNSCCs and lung squamous cell carcinomas (SCCs).
  • We detected loss of CSMD1 in a large proportion of HNSCCs (50%), lung (46%) and breast cancers (55%), and to a lesser extent in cutaneous SCCs (29%) and basal cell carcinomas (BCCs, 17%) using array-based comparative genomic hybridization (aCGH).
  • Studying the region more closely with quantitative real-time PCR (qPCR), the loss of CSMD1 increased to 80% in HNSCCs and 93% in lung SCCs.
  • CSMD1 expression was decreased in tumors compared to adjacent benign tissue (65%, 13/20) and was likely due to gene loss in 45% of cases (9/20).
  • We show loss of CSMD1 in primary HNSCC tissues, and document for the first time that CSMD1 is lost in breast, lung and cutaneous SCCs.
  • [MeSH-major] Breast Neoplasms / genetics. Head and Neck Neoplasms / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Chromosome Deletion. Comparative Genomic Hybridization. DNA, Neoplasm / analysis. Female. Gene Dosage. Gene Expression. Humans. Loss of Heterozygosity. Mouth Neoplasms / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism


69. Hill DA, Jarzembowski JA, Priest JR, Williams G, Schoettler P, Dehner LP: Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry. Am J Surg Pathol; 2008 Feb;32(2):282-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleuropulmonary blastoma (PPB) is a malignant neoplasm of the lung that presents in early childhood.
  • The early form of the disease, cystic type I PPB, can be clinically and pathologically deceptive because of its resemblance to some developmental lung cysts.
  • This study reviews 51 cases of type I PPB and 6 lung cysts from relatives of children with PPB.
  • Type I PPB is a delicate multilocular cyst with variable numbers of primitive mesenchymal cells beneath a benign epithelial surface.
  • Tumors in the youngest subset of patients, from birth to 2 months of age, are more uniform in composition and cellularity compared with those in older groups.
  • Early tumors have a subtle transition between normal developing lung and tumor, showing bland interstitial mesenchymal cells uniformly expanding the alveolar septa.
  • This phenomenon may explain the variable and sometimes sparse tumor cellularity seen in some type I PPBs.
  • Factors that control the balance between progression and regression may be important in predicting tumor behavior and determining which patients will benefit from adjuvant chemotherapy.
  • In the meantime, recognition of this lesion as a neoplasm with malignant potential rather than a developmental cystic malformation is vital so the child can receive complete excision and appropriate follow-up care.
  • [MeSH-major] Cystic Adenomatoid Malformation of Lung, Congenital / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology. Pulmonary Blastoma / pathology
  • [MeSH-minor] Age Factors. Child. Child, Preschool. Combined Modality Therapy. Cysts / pathology. Diagnosis, Differential. Family Health. Female. Genetic Predisposition to Disease. Humans. Infant. Infant, Newborn. International Cooperation. Male. Registries


70. Dim DC, Nugent SL, Peng HQ: Ganglioneuroma presenting as a paraesophageal mass lesion diagnosed by endoscopic ultrasound-guided fine needle aspiration cytology: a case report. Acta Cytol; 2010 May-Jun;54(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endoscopic ultrasound-guided fine needle aspiration is a well-established modality in detection and diagnosis of mediastinal lesions.
  • Ganglioneuroma is a benign, rare, soft tissue neoplasm arising from sympathetic ganglion cells, and complete surgical resection is considered to be curative.
  • Ganglioneuroma in a surgical specimen is a straightforward diagnosis; however, due to the infrequent occurrence of this entity, diagnosis by fine needle aspiration is more challenging.
  • A 75-year-old man with a history of adenocarcinoma of the lung was noted to have a mediastinal mass on chest computed tomography.
  • [MeSH-major] Ganglioneuroma / diagnosis. Mediastinal Neoplasms / pathology. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Endosonography. Esophagus / pathology. Humans. Male. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518419.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


71. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, Detterbeck F, American College of Chest Physicians: Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest; 2007 Sep;132(3 Suppl):178S-201S
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition).
  • BACKGROUND: Correctly staging lung cancer is important because the treatment options and the prognosis differ significantly by stage.
  • METHODS: Test characteristics for the noninvasive staging studies were updated from the first iteration of the lung cancer guidelines using systematic searches of the MEDLINE, HealthStar, and Cochrane Library databases up to May 2006, including selected metaanalyses, practice guidelines, and reviews.
  • CONCLUSIONS: CT scanning of the chest is useful in providing anatomic detail, but the accuracy of chest CT scanning in differentiating benign from malignant lymph nodes in the mediastinum is poor.
  • PET scanning has much better sensitivity and specificity than chest CT scanning for staging lung cancer in the mediastinum, and distant metastatic disease can be detected by PET scanning.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Clinical Trials as Topic. Diagnosis, Differential. Evidence-Based Medicine. Humans. Lymphatic Metastasis. Neoplasm Staging. Positron-Emission Tomography. Sensitivity and Specificity. Tomography, X-Ray Computed


72. Zhao X, Liu X, Guo W, Li X: [Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression]. Zhongguo Fei Ai Za Zhi; 2010 Sep;13(9):861-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: It has been shown that carbonic anhydrase IX (CAIX) was closely related to tumor hypoxia.
  • Proliferating cell nuclear antigen (Ki67) is considered to be an objective indicator which could reliable and comprehensive response to cell population proliferation; vascular endothelial growth factor (VEGF) was positively correlated with tumor angiogenesis.
  • The aim of this study is to investigate the significance of the expression of CAIX in non-small cell lung cancer (NSCLC) tissues by analyzing the correlation between CAIX and clinical characteristics of patients with lung cancer and VEGF, Ki67 expressions.
  • METHODS: CAIX, VEGF and Ki67 protein were detected in 76 cases of NSCLC and 10 cases of lung inflammatory pseudotumor by immunohistochemistry.
  • RESULTS: CAIX was expressed in 45 of 64 cases of NSCLC and not expressed in benign lesion pulmonary tissues.
  • CONCLUSIONS: Compared with benign lesion pulmonary tissue, the expression of CAIX in NSCLC tissues is significantly increased and is positively correlated with VEGF.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carbonic Anhydrases / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Gene Expression Regulation, Neoplastic. Ki-67 Antigen / metabolism. Lung Neoplasms / enzymology. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20840814.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Ki-67 Antigen; 0 / Vascular Endothelial Growth Factor A; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


73. Thomas R, Sharma N, Burke C, Maxwell D, Howlett DC: Parotid incidentaloma detected during thoracic PET imaging: how should these lesions be managed? Br J Hosp Med (Lond); 2010 May;71(5):292-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative positron emission tomography (PET) scanning of three patients with lung cancer revealed increased unilateral focal activity in a parotid gland.
  • Further investigation with ultrasound and core biopsy confirmed benign parotid neoplasm in all three cases.
  • [MeSH-major] Adenolymphoma / radionuclide imaging. Adenoma, Pleomorphic / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Parotid Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20448501.001).
  • [ISSN] 1750-8460
  • [Journal-full-title] British journal of hospital medicine (London, England : 2005)
  • [ISO-abbreviation] Br J Hosp Med (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


74. Murakami S, Saito H, Sakuma Y, Mizutani Y, Ishikawa Y, Kondou T, Oshita F, Yokose T, Kameda Y, Suga Y, Ito H, Tsuboi M, Nakayama H, Noda K, Yamada K: Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size. Eur J Radiol; 2010 Aug;75(2):e62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size.
  • BACKGROUND: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is commonly used to distinguish benign from malignant lesion.
  • We examined the relationship between SUVmax and proliferative activities as indicated by maximum diameter of tumor opacity on mediastinal-window images (TOM), Ki-67 index, and diameter of the pathological invasive area in lung adenocarcinomas <or=30 mm.
  • METHODS: Thin-section computed tomography (TS-CT) and FDG-PET were performed on 140 patients with resectable lung adenocarcinomas <or=30 mm between March 2006 and May 2008.
  • Tumors were classified as air-type or solid-type based on TS-CT findings.
  • RESULTS: SUVmax was significantly lower for air-type than for solid-type tumors (0.97 vs. 3.96, p<0.0001).
  • In solid-type tumors, SUVmax correlated with diameter of TOM (r=0.450, p<0.0001), Ki-67 index (r=0.567, p<0.0001), and diameter of the pathological invasive area (r=0.672, p<0.0001).
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Ki-67 Antigen / analysis. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20005653.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


75. Wang CP, Lee CY, Lou PJ, Yen RF, Hsiao JK, Ko JY: Role of ultrasound-guided fine needle aspiration in assessing the impalpable cervical node with increased 18F-fluorodeoxyglucose uptake on positron emission tomography scanning: preliminary communication. J Laryngol Otol; 2008 Dec;122(12):1349-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The underlying cancers included lung cancer (three patients), nasopharyngeal carcinoma (two), oesophageal cancer (two), buccal cancer (one), bladder cancer (one) and Langerhan's histiocytosis (one).
  • Cytological examination revealed a benign or reactive lesion in two patients, who at the time of writing were alive and well, 19 and 36 months after examination.
  • [MeSH-minor] Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Male. Middle Aged. Neck. Neoplasm Staging / methods. Radiopharmaceuticals. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Interventional. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549513.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


76. Vilmann P, Krasnik M, Larsen SS, Jacobsen GK, Clementsen P: Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy: a combined approach in the evaluation of mediastinal lesions. Endoscopy; 2005 Sep;37(9):833-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND STUDY AIMS: It would be desirable to develop minimally invasive methods of tissue diagnosis from lymph nodes as well as solid lesions in the mediastinum.
  • PATIENTS AND METHODS: EUS-FNA and EBUS-TBNA were compared in 33 patients, for the staging of lung cancer in patients with an established diagnosis of non-small-cell lung cancer (n = 20) or for diagnosis of a suspicious mediastinal lesion in patients with suspected lung cancer (n = 13).
  • EUS-FNA and EBUS-TBNA demonstrated cancer in 26 and 28 lesions, respectively, and benign cytology in 30 and 28 lesions, respectively.
  • Conversely, EUS-FNA diagnosed 12 additional cancer diagnoses, one suspicious and one specific benign diagnosis (sarcoidosis) in addition to EBUS-TBNA.
  • With a combined approach (EUS-FNA + EBUS-TBNA) in 28 of the 31 patients in whom a final diagnosis was obtained in the evaluation of mediastinal cancer, 20 patients were found to have mediastinal involvement, whereas no mediastinal metastases were found in eight patients.
  • The accuracy of EUS-FNA and EBUS-TBNA, in combination, for the diagnosis of mediastinal cancer was 100 % (95 % CI, 83 - 100 %).
  • A combined approach with both EUS-FNA and EBUS-TBNA may be able to replace more invasive methods for evaluating lung cancer patients with suspected hilar or mediastinal metastases, as well as for evaluating unclear mediastinal or hilar lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Non-Small-Cell Lung / pathology. Endosonography. Lung Neoplasms / pathology. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Bronchi. Esophagus. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116534.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. Sakurai H, Suzuki Y, Nonaka T, Ishikawa H, Shioya M, Kiyohara H, Katoh H, Nakayama Y, Hasegawa M, Nakano T: FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value. Gynecol Oncol; 2006 Mar;100(3):601-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
  • Rationale for FDG-PET was the presence of symptoms in 6 patients, abnormal serum tumor marker values in 13, abnormal lesions on other diagnostic imaging modalities in 19, and patient request in 2.
  • Maximum tumor diameter and tumor volume in the corresponding disease were estimated by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Four false-negative findings were seen for small lung metastases having a volume less than 1 cm3.
  • Three false-positive cases were a localized pneumonitis, a benign pubic bone fracture, and a fibrosis after interstitial brachytherapy.
  • Sensitivity for extrapelvic lymph node metastases was extremely high (100%); in contrast, sensitivity and specificity for lung and bone lesions were 75.0% (12/16) and 33.3% (1/3), respectively.
  • Regarding tumor volume measurement, good correlation between maxSUV on FDG-PET and tumor volume was obtained (lung metastases, P = 0.03; extrapelvic nodes, P < 0.0001).
  • This study suggests that FDG uptake is associated with tumor volume, and FDG-PET has limitations in the detection of lesions less than 1 cm3 or microscopic disease.
  • Careful diagnostic agreement between PET and CT/MRI for positive but benign lesions, such as inflammation and bone fracture, remains important.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Uterine Cervical Neoplasms / radionuclide imaging


78. Rotger A, Trifirò G, Travaini LL, de Cicco C, Paganelli G: Carcinoma, tuberculosis and elastofibroma in one patient: is [18F]FDG-PET/CT helpful? Rev Esp Med Nucl; 2009 Jan-Feb;28(1):22-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a woman with persistent dorsal pain and two solid lung lesions documented on multidetector CT which showed concomitant [18F]FDG uptake.
  • Incidentally, the patient also had an elastofibroma dorsi, a rare benign tumour which can also be a possible source of false results in the PET exam.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Diagnostic Errors. Fibroma / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Neoplasms, Multiple Primary / radionuclide imaging. Positron-Emission Tomography. Tomography, Spiral Computed. Tuberculosis, Lymph Node / radionuclide imaging. Tuberculosis, Pulmonary / radionuclide imaging
  • [MeSH-minor] Aged. Back Pain / etiology. Combined Modality Therapy. False Positive Reactions. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Incidental Findings. Lymphatic Metastasis. Neoplasm Staging. Radiopharmaceuticals. Tuberculoma / radionuclide imaging

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232174.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


79. Rad MH, Alizadeh E, Ilkhanizadeh B: Recurrent laryngeal papillomatosis with bronchopulmonary spread in a 70-year-old man. Tuberk Toraks; 2007;55(3):299-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent laryngeal papillomatosis (RRLP) which is characterized by wart like growths in the larynx is a rare benign disease seen in children and young adults and a few cases are reported in old aged adults.
  • The spread of RRLP throughout the respiratory tract occurs rarely; and involvement of the distal bronchi, bronchioles, and lung parenchyma is very rare.
  • Despite the rarity of this disease in adults, the correct diagnosis may be suggested by a characteristic combination of clinical, radiographic, and pathologic features.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Laryngeal papillomatosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978930.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


81. Choi DJ, Kwak JM, Kim J, Woo SU, Kim SH: Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer: its role in staging and impact on treatment strategy. J Surg Oncol; 2010 Nov 1;102(6):588-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Data were prospectively collected from 103 clinically T3/T4 mid or lower rectal cancer patients who had chest X-ray (CXR) and CT to evaluate lung metastasis.
  • The chest images were classified into four groups: metastasis, indeterminate, benign, and negative.
  • [MeSH-major] Lung Neoplasms / radiography. Lung Neoplasms / secondary. Neoplasm Staging / methods. Rectal Neoplasms / pathology. Tomography, X-Ray Computed


82. Rego A, Amado J, Esteves I, Almeida J, Furtado A, Couceiro A, Moura e Sá J: [Endobronchial granular cell tumor - what approach to take]. Rev Port Pneumol; 2006 Jul-Aug;12(4):463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endobronchial granular cell tumor - what approach to take].
  • [Transliterated title] Tumor de células granulares endobrônquico - Como abordamos?
  • Granular cell tumor is a mesenchymal neoplasm almost always benign, with tendency to recurrence.
  • Its occurrence in the lung is extremely rare.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / therapy. Granular Cell Tumor / diagnosis. Granular Cell Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969575.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


83. Koga T, Ushijima K, Kage M, Ichiki M, Kitajima T, Narita Y, Mizoguchi Y, Hanada M, Ehara R, Nishimura M, Takamori S, Aizawa H: Pulmonary metastasis of endometrial stromal sarcoma. Kurume Med J; 2006;53(3-4):95-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple round opacities suggestive of metastatic lung tumors were incidentally found on a chest x-ray film in a 43-year-old woman.
  • Morphological characteristics of the thracoscopically resected lung tumors suggested low-grade endometrial stromal sarcoma (ESS), and immunostaining revealed that the tumor cells were positive for progesterone and estrogen receptors, CD10 and vimentin, confirming a diagnosis of ESS.
  • ESS is an uncommon uterine neoplasm, however, may be mistaken as benign tumors such as epithelioid leiomyoma, and occasionally metastasizes to remote organs such as lungs even after long disease-free period, posing diagnostic challenge.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Sarcoma, Endometrial Stromal / pathology

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317938.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


84. Ung YC, Maziak DE, Vanderveen JA, Smith CA, Gulenchyn K, Lacchetti C, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care: 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst; 2007 Dec 5;99(23):1753-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review.
  • Lung cancer is the leading cause of cancer-related death in industrialized countries.
  • The overall mortality rate for lung cancer is high, and early diagnosis provides the best chance for survival.
  • Diagnostic tests guide lung cancer management decisions, and clinicians increasingly use diagnostic imaging in an effort to improve the management of patients with lung cancer.
  • This systematic review, an expansion of a health technology assessment conducted in 2001 by the Institute for Clinical and Evaluative Sciences, evaluates the accuracy and utility of 18fluorodeoxyglucose positron emission tomography (PET) in the diagnosis and staging of lung cancer.
  • PET appears to have high sensitivity and reasonable specificity for differentiating benign from malignant lesions as small as 1 cm.
  • PET appears superior to computed tomography imaging for mediastinal staging in non-small cell lung cancer (NSCLC).
  • PET has not been studied as extensively in patients with small-cell lung cancer, but the available data show that it has good accuracy in staging extensive- versus limited-stage disease.
  • Although the current evidence is conflicting, PET may improve results of early-stage lung cancer by identifying patients who have evidence of metastatic disease that is beyond the scope of surgical resection and that is not evident by standard preoperative staging procedures.
  • Further trials are necessary to establish the clinical utility of PET as part of the standard preoperative assessment of early-stage lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / secondary. Fluorodeoxyglucose F18. Lung Neoplasms / pathology. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis. Mediastinal Neoplasms / radionuclide imaging. Mediastinal Neoplasms / secondary. Neoplasm Staging. Radiopharmaceuticals. Sensitivity and Specificity. Solitary Pulmonary Nodule / pathology. Solitary Pulmonary Nodule / radionuclide imaging. Technology Assessment, Biomedical

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Dec 5;99(23):1741-3 [18042929.001]
  • (PMID = 18042932.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 101
  •  go-up   go-down


85. Osaka A, Hasegawa H, Yamada Y, Yanagihara K, Hayashi T, Mine M, Aoyama M, Sawada T, Kamihira S: A novel role of serum cytochrome c as a tumor marker in patients with operable cancer. J Cancer Res Clin Oncol; 2009 Mar;135(3):371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel role of serum cytochrome c as a tumor marker in patients with operable cancer.
  • PURPOSE: This study aimed to evaluate serum cytochrome c (cyto-c) levels as a novel role of tumor marker in patients with operable malignant tumors.
  • METHODS: Serum cyto-c levels and lactate dehydrogenase (LD) activity were measured in a total of 257 cases (232 malignant and 25 benign).
  • To identify the relationship between serum cyto-c and current tumor markers, six variables, such as gender, age, invasion, lymph node metastasis, distant metastasis, and LD, were analyzed by uni- and multivariate regression analysis methods.
  • RESULTS: The serum cyto-c level was significantly higher in patients with malignant tumors than patients with benign tumors (20.6 vs. 15.5 ng/mL; P = 0.017, Mann-Whitney U test).
  • CONCLUSION: Serum cyto-c is a potent tumor marker as a predictor for malignant potential in cancers.
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Disease Progression. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Predictive Value of Tests. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 2004 Apr;342(1-2):127-36 [15026273.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):3-15 [7856735.001]
  • [Cites] Arch Dis Child. 2006 Jun;91(6):469-72 [16443616.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):289-96 [12609567.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):605-17 [15234242.001]
  • [Cites] Int J Lab Hematol. 2009 Jun;31(3):307-14 [18279425.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Pediatr Infect Dis J. 2005 May;24(5):467-70 [15876954.001]
  • [Cites] Int J Cancer. 2005 Aug 20;116(2):167-73 [15800951.001]
  • [Cites] Appl Biochem Biotechnol. 2001 Feb;90(2):97-105 [11297391.001]
  • [Cites] Pancreas. 2000 Mar;20(2):117-22 [10707925.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jun;57(6):759-75 [18188561.001]
  • (PMID = 18825408.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 9007-43-6 / Cytochromes c
  •  go-up   go-down


86. Yoon HI, Yim JJ, Lee CT, Kim YW, Han SK, Shim YS, Kim YT, Sung SW, Kim JH, Yoo CG: Clinical characteristics of a second small nodule(s) associated with cT1-2N0M0 non-small-cell lung cancer. Lung; 2006 Sep-Oct;184(5):273-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics of a second small nodule(s) associated with cT1-2N0M0 non-small-cell lung cancer.
  • When a patient with cT(1-2)N(0)M(0) stage non-small-cell lung cancer (NSCLC) has a second small nodule(s), the treatment plan and prognosis depend largely on whether the nodule is benign or malignant.
  • Nodules were finally diagnosed as benign in 85% and malignant in 15%.
  • No significant differences in terms of gender, age, preoperative carcinoembryonic antigen (CEA) level, cell type, pathologic stages, shape, size, location and number of nodules, or the presence of calcification around nodules was observed between benign and malignant groups.
  • We suggest that if primary NSCLC is resectable, an effort should be made to confirm the pathologic diagnosis of nodules.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Prognosis. Retrospective Studies. Tomography, X-Ray Computed


87. Travaini LL, Petralia G, Trifirò G, Ravasi L, Galetta D, Carbone G, Falcini F, Spaggiari L, Bellomi M, Paganelli G: [18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning. Lung Cancer; 2008 Sep;61(3):362-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our retrospective study aims to assess multidetector computed tomography and 2-[(18)F]fluoro-2-deoxyglucose positron emission tomography/computed tomography ([(18)F]FDG-PET/CT) capacity to distinguish benign from malignant thymic lesions.
  • Student's t-test was performed on SUVbw max stratified for thymic epithelial tumors.
  • RESULTS: In the group of benign lesions MDCT correctly identified well-defined margins of masses in 8 out of 8 patients whereas [(18)F]FDG-PET/CT was negative in 7 out of 8 patients.
  • However, they are two non-invasive complementary techniques which can be used to differentiate benign from high-risk malignant thymic lesions.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358558.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


88. Unroe MA, Shofer SL, Wahidi MM: Training for endobronchial ultrasound: methods for proper training in new bronchoscopic techniques. Curr Opin Pulm Med; 2010 Jul;16(4):295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: The field of pulmonary medicine has experienced a rapid growth in innovative new technologies aimed at both diagnosis and treatment of airway, mediastinal and parenchymal disorders.
  • A growing body of evidence has demonstrated the efficacy of EBUS-TBNA in the diagnosis and staging of lung cancer, as well as the diagnosis of benign causes of mediastinal and hilar lymphadenopathy.
  • [MeSH-minor] Biopsy, Needle / standards. Clinical Competence. Computer Simulation. Evidence-Based Medicine. Humans. Lymph Nodes / pathology. Neoplasm Staging. Teaching / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531196.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


89. Parfitt JR, Bella AJ, Izawa JI, Wehrli BM: Malignant neoplasm of perivascular epithelioid cells of the liver. Arch Pathol Lab Med; 2006 Aug;130(8):1219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant neoplasm of perivascular epithelioid cells of the liver.
  • Although this group includes entities with distinct clinical features, such as angiomyolipoma, clear cell sugar tumor of the lung, and lymphangioleiomyomatosis, similar tumors have been documented in an increasing diversity of locations.
  • The term PEComa is now generally used in reference to these lesions that are not angiomyolipomas, clear cell sugar tumors, or lymphangioleiomyomatoses.
  • While most reported PEComas have behaved in a benign fashion, malignant PEComas have occasionally been documented.
  • We present a case of hepatic PEComa with benign histologic features, which nonetheless presented with metastases to multiple sites nearly 9 years later.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879028.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Lu CR, Hu YJ, Chen EG, Qiu YH, Ying KJ: [Measurement of exhaled volatile organic compounds in lung cancer patients]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Feb;33(2):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of exhaled volatile organic compounds in lung cancer patients].
  • OBJECTIVE: to study the characteristics of volatile organic compounds (VOCs) in exhaled breath of lung cancer patients, and therefore to explore its use in the diagnosis of the disease.
  • METHODS: from February 2007 to September 2009, 55 patients with lung cancer, 21 patients with benign lung diseases and 30 healthy controls were enrolled in our study.
  • RESULTS: heptanal was detected in 45 patients of the lung cancer group, 1 of the benign lung disease group, and 1 of the healthy control group.
  • The positive rate was higher in the lung cancer group as compared to the benign lung disease group and the healthy group combined (P < 0.05).
  • CONCLUSION: heptanal maybe a useful marker in VOCs from patients with lung cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Volatile Organic Compounds / analysis
  • [MeSH-minor] Breath Tests. Case-Control Studies. Exhalation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367949.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Volatile Organic Compounds; Adenocarcinoma of lung
  •  go-up   go-down


91. Medford AR, Bennett JA, Free CM, Agrawal S: Endobronchial ultrasound guided transbronchial needle aspiration. Postgrad Med J; 2010 Feb;86(1012):106-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Staging for non-small cell lung cancer (NSCLC) requires accurate assessment of the mediastinal lymph nodes which determines treatment and outcome.
  • EBUS-TBNA is therefore indicated for NSCLC staging, diagnosis of lung cancer when there is no endobronchial lesion, and diagnosis of both benign (especially tuberculosis and sarcoidosis) and malignant mediastinal lesions.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Bronchi / pathology. Bronchoscopy / methods. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Clinical Competence / standards. Costs and Cost Analysis. Education, Medical, Continuing. Equipment Design. Forecasting. Humans. Lymphatic Metastasis. Mediastinal Neoplasms / pathology. Neoplasm Staging. Specimen Handling. Ultrasonography, Interventional / economics. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145060.001).
  • [ISSN] 1469-0756
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 71
  •  go-up   go-down


92. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging.
  • The aim of this study was to evaluate the clinical value of tomographic (99m)Tc-octreotide acetate (hereafter, (99m)Tc-octreotide) scintigraphy in the detection of patients with suspected lung cancer in comparison with that of (18)F-FDG dual-head coincidence imaging (DHC).
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
  • RESULTS: Thirty-one of the 44 patients had lung cancer-6 with small cell lung cancer (SCLC) and 25 with non-small cell lung cancer (NSCLC).
  • Thirteen of the 44 patients had benign lung lesions.
  • In the 31 patients with malignant tumors, all 38 abnormal lymph nodes in 20 patients showed abnormal high focal uptake of (18)F-FDG; only 7 patients with 10 regional lymph adenopathies showed moderate uptake of (99m)Tc-octreotide.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • The final diagnosis was confirmed by histopathology or clinical follow-up.
  • CONCLUSION: The sensitivity of (99m)Tc-octreotide for the detection of lung cancer at the primary lesion was comparable with that of (18)F-FDG coincidence imaging.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


93. Flavin R, Finn S, McErlean A, Smyth P, Meaney J, O'Connell F, Kellett J, McGovern E, Gaffney E: Cannonball metastases with favourable prognosis. Ir J Med Sci; 2005 Jan-Mar;174(1):61-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Secondary 'cannonball' metastases to the lung are frequent and usually associated with disseminated malignancy and poor prognosis.
  • AIM: To report the case of a patient with metastatic pulmonary endometrial stromal sarcoma who had a previous hysterectomy for benign uterine fibroids and no past history of malignancy.
  • RESULT: A 70-year-old female presented with cannonball metastases in her lung.
  • Review of the original histology revealed endometrial stromal sarcoma, similar to the lung metastasis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Lung Neoplasms / secondary. Sarcoma, Endometrial Stromal / pathology. Sarcoma, Endometrial Stromal / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hysterectomy. Leiomyoma / pathology. Leiomyoma / surgery. Megestrol Acetate / therapeutic use. Neoplasm Metastasis. Prognosis. Sarcoma

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1996 Dec;103(12):1252-4 [8968246.001]
  • [Cites] Hum Pathol. 1991 Mar;22(3):224-30 [1706303.001]
  • [Cites] Virchows Arch. 2003 Feb;442(2):173-8 [12596070.001]
  • [Cites] Am J Surg Pathol. 1989 Feb;13(2):133-40 [2916727.001]
  • [Cites] J Clin Pathol. 1999 Feb;52(2):147-8 [10396245.001]
  • [Cites] Neurol Med Chir (Tokyo). 1986 Jul;26(7):571-4 [2430224.001]
  • [Cites] Gynecol Oncol. 1997 Feb;64(2):262-4 [9038273.001]
  • [Cites] Gynecol Oncol. 1990 Aug;38(2):273-7 [2167285.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):415-38 [2327549.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):440-9 [11914621.001]
  • [Cites] Pathol Int. 1998 Apr;48(4):297-302 [9648159.001]
  • [Cites] Jpn J Clin Oncol. 2002 Feb;32(2):71-4 [11948233.001]
  • (PMID = 15868893.001).
  • [ISSN] 0021-1265
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


94. Donoiu I, Radu RI, Giucă A, Popescu M, Ionescu DD: Invasive thymoma. Rom J Morphol Embryol; 2010;51(3):573-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymomas are rare tumors of the thymic epithelium with a broad spectrum of morphological and clinical features.
  • Despite a benign histological appearance, it can invade nearby structures or metastasize.
  • According to the WHO Classification, there are six histologic types of thymic epithelial tumors.
  • [MeSH-minor] Humans. Lung / pathology. Lung / radiography. Middle Aged. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20809041.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


95. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for CD34, CD99, and bcl-2.
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • Initial chemotherapies failed to control the tumor.
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


96. Hürtgen M, Friedel G, Witte B, Toomes H, Fritz P: Systematic Video-Assisted Mediastinoscopic Lymphadenectomy (VAMLA). Thorac Surg Sci; 2005;2:Doc02
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accurate mediastinal lymph node dissection during thoracotomy is mandatory for staging and for adjuvant therapy in lung cancer.
  • Pre-therapeutic staging for neoadjuvant therapy or for video assisted thoracoscopic resection of lung cancer is achieved usually by CT-scan and mediastinoscopy.
  • In patients receiving tumour resection subsequently to VAMLA, radicality of the previous mediastinoscopic dissection was controlled during thoracotomy.37 patients underwent video-assisted mediastinoscopy from June 1999 to April 2000.
  • Mean duration of anaesthesia was 84.6 (SD 35.8) minutes.In 7 patients radical lymphadenectomy was not intended because of bulky nodal disease or benign disease.
  • The remaining 30 patients underwent complete systematic nodal dissection as VAMLA.18 patients received tumour resection subsequently (12 right- and 6 left-sided thoracotomies).
  • None of these nodes was positive for tumour.Average weight of the tissue that was harvested by VAMLA was 10.1 g (2.2-23.7, SD 6.3).
  • This is comparable to our historical data from open lymphadenectomy.One palsy of the recurrent nerve in a patient with extensive preparation of the nerve and resection of 11 left-sided enlarged nodes was the only severe complication in this series.VAMLA seems to accomplish mediastinal nodal dissection comparable to open lymphadenectomy and supports video assisted surgery for lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1135-40 [10838529.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Nov;12(5):706-12 [9458140.001]
  • [Cites] Thorac Cardiovasc Surg. 1999 Feb;47(1):42-7 [10218620.001]
  • [Cites] Chest. 1975 Mar;67(3):365-6 [1112136.001]
  • [Cites] Thoraxchir Vask Chir. 1965 Dec;13(6):401-7 [5222569.001]
  • [Cites] Chest. 1997 Dec;112(6):1480-6 [9404742.001]
  • [Cites] Eur Respir J. 1997 Nov;10(11):2529-34 [9426090.001]
  • [Cites] Schweiz Med Wochenschr. 1998 Jun 6;128(23):895-9 [9658517.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Feb;21(2):348-51 [11825753.001]
  • [Cites] Chirurg. 1990 Apr;61(4):308-11 [2347266.001]
  • [Cites] J Laryngol Otol. 1989 Mar;103(3):312-5 [2703776.001]
  • [Cites] Surgery. 1987 Oct;102(4):652-9 [2821640.001]
  • [Cites] J Thorac Cardiovasc Surg. 1987 Nov;94(5):673-8 [3669695.001]
  • [Cites] Dtsch Med Wochenschr. 1967 Dec 22;92(51):2358-61 [6073576.001]
  • [Cites] Eur J Cardiothorac Surg. 1994;8(1):37-42 [8136168.001]
  • [Cites] Ann Thorac Surg. 1993 Apr;55(4):961-6 [8385446.001]
  • [Cites] Eur Respir J. 1996 Dec;9(12):2560-4 [8980969.001]
  • [Cites] Radiology. 1997 Feb;202(2):441-6 [9015071.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Aug;12(2):224-7 [9288511.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Apr;10(2):71-5 [10789576.001]
  • [Cites] Eur Respir J. 1997 Jul;10(7):1547-51 [9230245.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Jul;12(1):92-7 [9262087.001]
  • (PMID = 21289921.001).
  • [ISSN] 1862-4006
  • [Journal-full-title] Thoracic surgical science
  • [ISO-abbreviation] Thorac Surg Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3011310
  • [Keywords] NOTNLM ; carcinoma, non-small-cell lung / lung neoplasm / mediastinoscopy / neoplasm staging / video-assisted surgery
  •  go-up   go-down


97. Chen Y, Zhang H, Xu A, Li N, Liu J, Liu C, Lv D, Wu S, Huang L, Yang S, He D, Xiao X: Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer; 2006 Oct;54(1):95-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer.
  • To identify potential biomarkers related with lung cancer metastasis, conditional media (CM) proteins collected from a primary non-small cell lung cancer (NSCLC) cell line NCI-H226 and its brain metastatic subline H226Br were analyzed by one-dimensional electrophoresis (1-D PAGE) and matrix-assisted laser desorption/time of flight mass spectrometry (MALDI-TOF-MS).
  • Twelve biomarkers were identified, of which l-lactate dehydrogenase B (LDHB) chain was significantly up-regulated in the CM of H226Br cell and was further validated in 105 lung cancer, 93 non-lung cancer, 41 benign lung disease, as well as 65 healthy individuals sera using enzyme-linked immunosorbent assay (ELISA).
  • At the cutoff point 0.260 (OD value) on the receiver operating characteristic (ROC) curve, LDHB could comparatively discriminate lung cancer from benign lung disease and healthy control groups with sensitivity 81%, specificity 70% and total accuracy 76%.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / enzymology. L-Lactate Dehydrogenase / blood. Lung Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Electrophoresis, Polyacrylamide Gel. Enzyme-Linked Immunosorbent Assay. Female. Humans. Isoenzymes / blood. Male. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890323.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 1
  •  go-up   go-down


98. Oda M: [Completion pneumonectomy]. Kyobu Geka; 2010 Jul;63(8 Suppl):719-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Completion pneumonectomy (CP) is defined as the operation intended to remove the reminder of the lung after a previous operation.
  • The indications of CP include both benign and malignant diseases and it is more demanding technical procedure with high morbidity and mortality compared to standardized pneumonectomy.
  • [MeSH-major] Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Humans. Neoplasm, Residual / surgery. Reoperation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715447.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Fnini S, Labsaili N, Messoudi A, Largab A: [Giant cell tumor of the thumb proximal phalanx: resection-iliac graft and double arthrodesis]. Chir Main; 2008 Feb;27(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant cell tumor of the thumb proximal phalanx: resection-iliac graft and double arthrodesis].
  • [Transliterated title] Tumeur à cellules géantes de la phalange proximale du pouce: résection-autogreffe iliaque et arthrodèse bipolaire.
  • Giant cell tumours (GCT) of bone are frequent, with variable behaviour, high risk of recurrence and an often benign histological appearance.
  • No recurrence or lung metastasis was seen at 18 months follow-up.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone. Thumb
  • [MeSH-minor] Arthrodesis. Biopsy. Bone Nails. Bone Transplantation. Finger Joint. Follow-Up Studies. Fracture Fixation, Internal / instrumentation. Fractures, Spontaneous / etiology. Fractures, Spontaneous / surgery. Humans. Male. Metacarpophalangeal Joint. Middle Aged. Neoplasm Staging. Patient Satisfaction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248835.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


100. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE: Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology; 2010 Apr;42(3):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
  • AIMS: Cytology fails to detect neoplastic cells in 40-50% of cases of malignant pleural effusion, a condition that frequently accompanies lung adenocarcinoma.
  • Published reports of diagnostic sensitivity of various tumour markers are inconsistent, and optimal cut-off points have not been determined.
  • This study aimed to evaluate the ability of three markers to discriminate lung adenocarcinoma-associated malignant pleural effusion (LAC-MPE) from benign effusion.
  • METHODS: Pleural effusion samples were collected from 41 patients with LAC-MPE, and from 93 with various benign conditions.
  • RESULTS: Her-2/neu, Cyfra 21-1, and CEA vary in their diagnostic accuracy to differentiate LAC-MPE from benign pleural effusion: 79.85%, 88.81%, and 94.03%, respectively.
  • The results of the present study may help clinicians decide whether to obtain a cytological/histological specimen by invasive means to investigate a possible diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / analysis. Carcinoembryonic Antigen / analysis. Keratin-19 / analysis. Lung Neoplasms / diagnosis. Pleural Effusion / metabolism. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350214.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / antigen CYFRA21.1; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down






Advertisement